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ABSTRACT 
Studies on Encephalomyocarditis Virus-Induced 
Diabetes in Mice 
by 
John H. Huffman, Doctor of Philosophy 
Utah State University, 1988 
Major Professor: Dr. Reed P. Warren 
Department: Biology 
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The D-variant of encephalomyocarditis (EMC-D) virus was given to 
SJUJ mice by the artificial , intraperitoneal (ip) route of infection , or by the 
natural routes of infection per os (po) or intranasal (i.n .), in comparable 
concentrations. The po route of infection was found to be ineffective. Mice 
given virus by either the ip or i.n. routes of infection became diabetic. Mice 
were more resistant to the infectious and diabetogenic properties of the virus 
when given by the i.n . than when given by the ip route. Glycosuria in mice 
given virus i.n. usually lagged one day behind that in mice given virus ip. 
Measurement of glucose in mouse urine by use of Diastix® reagent 
strips was found to be a reliable indicator of diabetes. This test was easily and 
quickly accomplished without harm or pain to the mice. 
Crude virus preparations were compared to purified virus preparations 
for their diabetogenic and infectious properties in mice. No statistically 
significant differences in either parameter were observed. Virus prepared by a 
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single passage in BHK-21 cells was fully diabetogenic, contrary to a 
previously published report. 
Male SJUJ mice were infected with a diabetogenic dose of EMC-D 
virus by the i.n. route. Relative times of development of virus infection and 
mouse resistance parameters were compared to the time of development of 
signs of diabetes in the mice. A rapid decrease of plasma interferon titer 
corresponded to the time of development of signs of diabetes in the infected 
mice. Whether this was coincidental or has some significance in development 
of diabetes is unknown. 
Tissue sections from pancreas, spleen , kidney, liver, lung , heart, and 
thymus were studied by immunohistochemical staining techniques for the 
presence of virus antigen, insulin , and the three types of mouse interferon (a, 
p, andy). 
Glucose was excreted in the saliva of mice with glycosuria. Previous 
reports of this excretion in diabetic mice have not been found in the literature. 
Mice without glycosuria did not excrete measurable (by Clinistix® or Diastix®) 
glucose in saliva. 
Some mice were able to control the polyuria, polydipsia, and 
polyphagia normally seen in diabetes mellitus. These mice eventually 
reverted from having signs of diabetes to a normal state of plasma glucose 
and urine devoid of glucose. The mechanisms by which the mice were able to 
do this are unknown at this time. 
(133 pages) 
CHAPTER I 
INTRODUCTION 
The disease known as diabetes is actually a collection of many different 
disorders, all of which cause excessive excretion of urine. The definition of 
diabetes given in Webster's Ninth New Collegiate Dictionary (1, p. 349) is 
[L, fr. Gk diabetes , lit., siphon, fr. diabainein] (15c) 
: any of various abnormal conditions characterized 
by the secretion and excretion of excessive 
amounts of urine; esp : DIABETES MELLITUS 
Taber (2, p. D-20) provides 10 terms to explain the different entities known 
collectively as diabetes. The definition of diabetes mellitus, or true diabetes, 
follows. 
A disorder of carbohydrate metabolism 
characterized by hyperglycemia, and glycosuria, 
resulting from inadequate production or utilization 
of insulin. 
Diabetes mellitus is further characterized into two general subcategories, 
depending on the patient's requirement for externally administered insulin to 
control hyperglycemia. These categories are juvenile-onset (type-1, or 
insulin-dependent) diabetes and adult-onset (type-2, or noninsulin-
dependent) diabetes. This investigation is limited to a study of the juvenile-
onset category of diabetes mellitus using an animal model. 
Although diabetes mellitus is known to involve inadequate production 
or utilization of insulin, the initiation of the inadequacies of insulin activity is not 
well-understood. In 1927, Gunderson (3) proposed that viral infection could 
initiate the onset of diabetes. Although no virus had been identified as a 
causative agent of diabetes, he made the observation that an increased 
frequency of diabetes closely followed epidemics of mumps in children. More 
recently, Craighead (4) reviewed findings which support viral infections as one 
possible cause of juvenile-onset diabetes. Mumps outbreaks have often been 
noted in close association to development of symptoms of diabetes. However, 
there is a lack of documented lesions in the islets of Langerhans in the few 
autopsy reports on individuals dying early in the course of infection with 
mumps virus . Other viruses common to childhood epidemic disease have 
also been implicated in juvenile-onset diabetes by close association in time 
with onset and/or by increased prevalence and higher titers of virus-specific 
antibodies. Relevant viruses known to cause pancreatitis in man include, in 
addition to mumps virus, rubella virus, coxsackievirus group B type 4, and 
cytomegalovirus (4). 
To effectively study virus as a possible cause of diabetes mellitus, it is 
necessary to use an animal/virus model system. There are animal models for 
the study of vi rally induced diabetes that employ lymphocytic choriomeningitis 
virus (LCMV) (5), Venezuelan encephalitis virus (6), rubella virus (7), 
coxsackievirus 84 (8), foot-and-mouth disease virus (9), reovirus (1 0), and 
encephalomyocarditis (EMC) virus (11 ). Each is characterized by particular 
advantages and disadvantages. Thus, a model system was chosen that 
would best answer the questions posed by the study prospectus. 
The mouse model using EMC virus was chosen for this study because 
EMC virus is a murine enterovirus (12), and is natural to the model host. It has 
also been isolated from stools of human beings and from several other genera 
of vertebrates, presumably occuring there as the result of natural infection 
(12) . In addition, Yoon et al. (13) found neutralizing antibody titers to EMC 
virus in 12% of the juvenile diabetics they studied in contrast to only 6% of 
their control subjects. This virus/mouse model is also the most widely studied 
of such models. 
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It is obvious from the studies involving the EMC virus/mouse model that 
either the infectious virus particle itself or something in the cells in which the 
virus grows is one of the determining factors in whether or not the viral 
preparation will cause diabetes. In all previous studies, it was assumed that 
the virus particle itself was responsible for the clinical signs of diabetes. None 
of the investigators speculated that the extraneous material (from the cell 
culture in which the virus was propagated) had any bearing on the 
diabetogenicity of the virus preparation. The infecting virus particles have yet 
to be purified from the cell milieu in which the virus inoculum was grown, 
despite the fact that Giron et al. (1 4) found extreme differences in the 
diabetogenicity of EMC virus after single passages in different cell lines. Thus, 
it is important to determine if purified virus retains diabetogenic properties. 
Interferon (IFN) has been implicated (1 4, 15, 16, 17, 1 8) in the 
mechanism of induction of the diabetic state when mice are infected with EMC 
virus. Since there have been only superficial investigations into the roll of IFN, 
more thorough investigations should be made into the type of IFN which is 
produced at specific times relative to diabetogenic infections by EMC virus. 
Results should then be compared to the type of IFN that is produced at similar 
times in non-diabetogenic infections by EMC virus. In addition, knowing which 
tissues are involved in the production of the IFN at those specific times could 
be enlightening. 
Host factors such as immune competence (1 9, 20) are certainly 
involved in diabetogenicity following EMC virus infection ; however, there are 
no investigations of the status of the cellular- or the humoral-immune system 
components during such diabetogenic infections. 
All reported studies of EMC virus-induced diabetes have employed an 
artificial means, intraperitoneal (ip) injection, for introduction of the virus into 
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the host. However, a more relevant study of virus-induced diabetes might be 
possible if the virus were introduced by a natural route of infection. 
The objectives of this study are 1) to determine if a natural route of 
infection can be reliably used to induce diabetes in mice and if so, to use that 
route of infection to continue with the other objectives of the study; 2) to 
determine if the virus particle is intrinsically diabetogenic or if it must be 
introduced along with supposedly extraneous materials present in the virus 
preparation; 3) to characterize host-defense activities in relationship to the 
EMC virus infection and development of diabetes; 4) to substantiate findings 
by others and ex1end the description of the characteristics of the EMC-D 
virus/mouse model of diabetes; and 5) to use reagent strips used for urinalysis 
in humans (Ciinistix® and Diastix®) to determine their reliability as an 
indicator of diabetes in mice. 
This study is important as a means to elucidate mechanisms involved in 
virus-induced diabetes in mice. If these mechanisms could be determined in 
animals , it would then be possible to intelligently design experiments to 
combat virally induced diabetes in humans. 
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CHAPTER II 
REVIEW OF THE LITERATURE 
Diabetes Mellitus. Definition. There are many definitions of 
diabetes, depending on the writer and the time that the definition was written . 
In Webster's New Collegiate Dictionarv , copyright 1961 (21 , p. 228) , the 
definition is as follows : 
di'a·be"tes ... A disease attended with a persistent, excessive 
discharge of urine ; specif., di"a·be "tes mef.li"tus .. . , or sugar 
diabetes, a grave form in which the body is unable to utilize 
properly the carbohydrates in the diet due to failure in the 
secretion of insulin by the pancreas. It is marked by sugar in the 
urine, excessive thirst and hunger, and progressive emaciation . 
Currently, definitions by investigators more closely approximate that of 
Berhanu and Olefsky (22, p. 265) : 
Diabetes mellitus is a complex disorder characterized by 
alterations in carbohydrate , lipid, and protein metabolism 
resulting from a deficiency of insulin or its cellular metabolic 
effects. As a function of time, these metabolic derangements 
lead to the development of chronic degenerative changes in the 
eyes, kidneys, nerves, and blood vessels, and often result in the 
well-known chronic clinical complications of diabetes including 
blindness, renal failure, peripheral and autonomic neuropathy, 
and occlusive peripheral vascular and coronary artery disease. 
Although diabetes mellitus has been recognized for several 
centuries, our concepts regarding its etiology and pathogenesis 
continue to undergo major changes. 
The vivid description of the disease made by Aretaeus could almost 
serve as a definition and since it makes so many valid points regarding the 
disease, it is quoted here (23, flyleaf) . 
Diabetes is a wonderful affection, not very frequent among men , 
being a melting down of the flesh and limbs into urine. Its cause 
is of a cold and humid nature, as in dropsy. The course is the 
common one, namely, the kidneys and bladder; for the patients 
never stop making water, but the flow is incessant, as if from the 
5 
opening of aqueducts. The nature of the disease, then , is 
chronic, and it takes a long period to form; but the patient is 
short-lived, if the constitution of the disease be completely 
established; for the melting is rapid , the death speedy. 
Moreover, life is disgusting and painful ; thirst unquenchable ; 
excessive drinking , which , however, is disproportionate to the 
large quantity of urine, for more urine is passed ; and one cannot 
stop them either from drinking or making water. Or if for a time 
they abstain from drinking, their mouths become parched and 
their bodies dry, the viscera seem as if scorched up; they are 
affected with nausea, restlessness, and a burning thirst ; and at 
no distant term they expire. 
Hence, the disease appears to me to have got the name 
'diabetes' as if from the Greek word 8taP1l1:1l<Y (which signifies a 
siphon), because the fluid does not remain in the body, but uses 
the man's body as a ladder (8uxPa9pJ1) , whereby to leave it. 
They stand out for a certain time, but not very long, for they pass 
urine with pain, and the emaciation is dreadful; nor does any 
great portion of flesh pass out along with the urine. 
The cause of it may be, that some of the acute diseases may 
have terminated in this : and during the crisis the diseases may 
have left some malignity lurking in the part. It is not improbable, 
also, that something pernicious, derived from the other diseases 
which attack the bladder and kidneys , may sometimes prove the 
cause of this affection. 
Aretaeus the Cappadocian, A.D. 81-138 
History. A disease, now termed diabetes, was described in the Ebers 
Papyrus in 1500 B.C. However, diabetes seems to be a "disease of 
civilization" since its prevalence increases as urbanization , working patterns, 
and diet change from primitive to civilized modes (24) . 
The name diabetes was applied to the disease by Aretaeus the 
Cappadocian, A.D. 81-138 (23, 24). The Greek word for honey, mellitus, was 
added when a sweet substance was noted in the urine of patients with 
diabetes (24). Butterfield (25) provided a succinct history of developments in 
the study of diabetes. He related (25, p. 78) that in 1798 Rollo (26) described 
diabetes as "a morbid condition of the stomach forming or developing from 
vegetable substances, saccharine matter which is quickly separated as a 
foreign body by the kidneys." It was not until 1851 that Bouchardat (27) 
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attributed diabetes mellitus to disease of the pancreas, although he wrongfully 
ascribed it to a failure of the external secretion of the pancreas. Von Maring 
and Minkowski (28) found that pancreatectomy in dogs caused permanent 
diabetes of a severe nature. They also reported that ligation of the duct led to 
atrophy of the pancreas but did not cause diabetes. They recognized that the 
pancreas has a function that is essential for the utilization of sugar by the 
organism. They evidently did not connect the cells (now called islets of 
Langerhans) previously reported by Langerhans (29) with their newly 
discovered function of the pancreas. Laguesse (30), however, suggested that 
the islets of Langerhans produce a hormone and Schafer (31) related that 
hormone to carbohydrate metabolism. It was not until 1921 that Banting and 
Best (32, 33) extracted insulin from the pancreas of dogs and demonstrated its 
hypoglycemic activity. Sanger (34, 35) determined the structure of insulin in 
the mid-1950s. 
According to Berhanu and Olefsky (22) it was thought, immediately 
following the reports of discovery of this pancreatic extract by Banting and Best 
(32, 33) , that all diabetes mellitus resulted from insulin deficiency. Himsworth 
(36) was one of the first to recognize that diabetes is a heterogeneous 
disorder when he pointed out that diabetes could be differentiated into 
"insulin-sensitive" and "insulin-insensitive" types on the basis of blood-glucose 
response to insulin administered after an oral glucose load. He later 
suggested that insulin insensitivity, not insulin deficiency, is present in many 
diabetics who are nonketotic and of middle age. This view was strengthened 
when Yalow and Berson (37) reported a method (insulin radioimmunoassay) 
by which endogenous insulin could be measured in the plasma, and it was 
found that on the average higher levels of insulin occur in patients with the 
r adult-onset form of the disease than in normal controls. 
li 
7 
Epidemiology. The National Diabetes Data Group (NDDG) reported in 
1985 (38) that approximately 5.8 million people in the U.S. had been 
diagnosed as being diabetic and an additional 4-5 million with diabetes 
remained undiagnosed. They reported 4 main types of diabetes 1) insulin-
dependent diabetes mellitus (lOOM), which comprises 5-10% of all cases of 
diabetes in the U.S.; 2) noninsulin-dependent diabetes mellitus (NIDDM) , 
which comprises most of the remaining cases; 3) gestational diabetes (GDM), 
which is a transient condition during pregnancy, occurring in 2-5% of all 
pregnancies; and 4) a type of diabetes that is secondary to or associated with 
the other conditions and makes up about 2% of the cases. In addition to these 
4 types of diabetes, impaired glucose tolerance (IGT) affects those persons 
with glucose tolerance between normal and diabetic (38). 
Approximately 500,000 persons each year are diagnosed as diabetic. 
The annual incidence is 12-14/100,000 children ages 0-16 years; by age 20, 
0.3% of persons in the U.S. have lOOM. Two and thirty-five hundredths 
percent of the population of the U.S. is diagnosed as having NIDDM, and 
those 65 years and older with N lOOM make up 8.6% of the population (38). 
Insulin-dependent diabetes mellitus tends to run in families but does 
not have a clear genetic etiology or a consistent mode of inheritance (39). The 
incidence of lOOM is similar in males and females and is 1.5 times higher in 
whites than in blacks, but incidence rates vary widely internationally. 
Individuals with particular human leucocyte antigen (HLA) types, especially 
DR3 and DR4, are at increased risk for development of lOOM. Additional risk 
factors may be advanced maternal age and the presence of islet cell 
antibodies. Siblings of diabetic children have a 7 to 18 times greater risk of 
developing lOOM than children of the general population. However, only 
about 1 child in 50 who is a brother or sister of an lOOM patient will develop 
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lOOM. lOOM is one of the major chronic diseases of children , having a risk 
similar to that of developing cancer in childhood but having a much greater 
risk than other well-known diseases (cystic fibrosis , leukemia, rheumatoid 
arthritis , muscular dystrophy, and Hodgkin's disease) (38). 
Only limited data concerning the prevalence of lOOM in the U.S. are 
available but results obtained are consistent. One child in 600 of school age 
has lOOM. Very little is known concerning the prevalence of lOOM in adults 
(38) . 
Diabetes was the seventh leading underlying cause of death in the U.S. 
in 1982, leading to 34,583 deaths. An additional 95,000 deaths were listed 
with diabetes as a contributing cause (38) . Mortality among white male and 
female lOOM patients was 5 to 11 times greater than in nondiabetics and the 
rates for blacks with lOOM were about two times higher than those for whites. 
Below age 20, the primary cause of death in lOOM was acute diabetic 
complications, but at older ages renal disease accounted for nearly half of the 
deaths. The frequency of renal disease deaths was 500 times higher and of 
cardiovascular disease deaths was 13 times higher in lOOM patients than in 
the general population (38) . 
Diagnosis. A number of prospective observational studies (40, 41 , 42, 
43, 44) have led to the tentative conclusion that the pathologic consequences 
of diabetes are most likely to occur when blood glucose levels are excessive 
over extended periods of time. Consequently, the World Health Organization 
(WHO) and the NDDG have recommended criteria for the diagnosis of 
diabetes based on plasma glucose levels which are believed to be predictive 
of the complications of diabetes. The NDDG and WHO do not consider 
diagnostic criteria that employ urine glucose or casual and postprandial 
glucose values to be adequate for the diagnosis of diabetes (38) . They 
9 
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recommend that diagnosis in a clin ical setting be made by one of the 
following: 1) the presence of the classic symptoms of diabetes {polyuria, 
po lydipsia, ketonuria, and rapid weight loss) together with gross and 
unequivocal elevation of plasma glucose, e.g., postprandial or random plasma 
glucose concentration> 200 mg/dl (11 .1 mmoi/L) ; 2) elevated fasting glucose 
concentration on more than one occasion as follows : venous plasma ~140 
mg/dl (7.8 mmoi/L), venous whole blood ~120 mg/dl (6.7 mmoi/L). or capillary 
whole blood ~120 mg/dl (6.7 mmoi/L) ; or 3) when the fasting glucose 
concentration is less than that which is diagnostic of diabetes (see no. 2 
above) , an abnormal oral glucose tolerance test must meet the following 
criteria: venous plasma ~200 mg/dl (11 .1 mmoi/L), or venous whole blood ~ 
180 mg/dl (1 0.0 mmoi/L) , or capillary whole blood ~200 mg/dl (11 .1 mmoi/L). 
To meet these latter criteria, the NDDG requires both a 2-hour sample and 
some other sample taken between administration of the 75-gram glucose 
dose and the 2-hour sample, while the WHO requires only a 2-hour sample. 
Interpretation of the results of a single glucose tolerance test should be 
done with care because there have been reports of a lack of reproducibility of 
this testing in normal subjects and in diabetic patients (45). McDonald et al. 
(45) found that the degree of carbohydrate intolerance can fluctuate in 
diabetics from a normal test at one time to marked intolerance in the same 
patient at another time. There have been occasional reports of total remission 
of severe diabetes (46, 47, 48) , some of which may have been based on non-
reproducible glucose tolerance tests. 
Complications of diabetes. Diabetes is the leading cause of new cases 
of blindness in people of ages 20-74 years in the U.S. Other common 
complications are acidosis and coma, kidney disease, peripheral vascular 
disease, heart disease, hypertension, and cerebrovascular disease. It has 
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been reported that infections occur more often in diabetics than in 
nondiabetics but "many published inferences about infectious consequences 
of diabetes go beyond what available data permit. " (49, p. XIX-1) . Most types 
of infections are no more common in diabetics than in nondiabetics. However, 
kidney and urinary-tract infections do appear at a relatively high rate in 
diabetics; and diabetes is a pre-existing condition in a significant proportion of 
patients with certain fungal infections, as well as in some unusual clinical 
entities such as invasive eX1ernal otitis (38). 
Economic aspects of diabetes. It is difficult to estimate the full economic 
impact of diabetes because it is so closely related to other acute and chronic 
conditions that may also be the reason for medical expenses. The lowest 
estimates of costs directly attributable to diabetes in the U.S. are $13.8 billion 
annually, 3.6% of total health costs. Medical care expenses specifically for 
diabetes account for $7.4 billion, while $6.3 billion is due to indirect costs due 
to disability and premature death among diabetics. All costs incurred by 
diabetics for medical care are estimated to be about 2-times the above (38) . 
Animal Models of Virus-Induced Diabetes Mellitus. Several 
animal models for the study of virus-induced diabetes mellitus have been 
described. Some of these models have not been well-developed and have 
not received attention by many investigators. Such models include 
lymphocytic choriomeningitis virus in mice (5), foot-and-mouth disease virus in 
cattle (9), rubella virus in rabbits (7), reovirus in infant mice (1 0). and a model 
described by Rayfield et al. (6) of Venezuelan equine encephalitis virus in 
hamsters. 
Another model of virus-associated diabetes mellitus is the 
coxsackievirus (CV) type B infection in mice (8) . This model is especially 
interesting in light of the fact that some investigators (50 , 51) found 
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correlations between antibodies to CV type 84 and the onset of insulin -
dependent diabetes in humans. They also found a seasonal incidence of 
insulin-dependent diabetes mellitus with significant positive correlation with 
the annual prevalence data for this virus, but not for other types of viral 
infection. Other workers (52, 53, 54, 55, 56) have not been able to confirm 
those findings. Interestingly, however, Yoon et al. (57) isolated CV type 84 
from the postmortem pancreas of a boy who had been admitted to a hospital in 
diabetic ketoacidosis. The boy was admitted within three days of onset of 
symptoms of a flu-like illness. The isolated virus caused diabetic signs when 
injected into mice. Serum samples from the boy had a titer of neutralizing 
antibody to the virus of less than 4 on the second hospital day and 32 on the 
8th hospital day, the day of his death. This is the best evidence to date that a 
virus is involved in the initiation of diabetes in man. 
Some workers have not been able to obtain hyperglycemic glucose 
levels in mice injected with CV (58, 59) . Yoon et al. (60) found that repeated 
passage of CV type 84 in mouse pancreatic beta cells led to the isolation of a 
diabetogenic variant of this virus, which could then be used to induce diabetes 
signs in several inbred strains of mice. In this and another study (61) they 
found that repeated passage of CV or EMC virus in secondary mouse embryo 
cells did not increase diabetogenic capabilities. 
The EMC virus/mouse model for juvenile-onset diabetes mellitus has 
been the most studied animal model for diabetes. Although a great deal has 
been published regarding this model system there are many questions to be 
answered before results obtained from the model can be properly interpreted. 
Some of these questions will be addressed in the remainder of this chapter. 
Effects of Virus Strain on EMC Virus-Caused Diabetes. The 
virus strain is important in determining whether or not an infection will result in 
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the diabetic syndrome. The first report regarding the diabetogenic nature of 
EMC virus (11) specified that the diabetogenic activity is seen only in a variant 
selected by harvesting the virus from repeated passages in the myocardium of 
infected mice. Craighead and Mclane (11) named it the M variant (from 
myocardium) . Many other investigators have since used the M variant to 
successfully induce diabetes in various mouse strains ; however, some mouse 
strains have consistently been resistant to the diabetogenic effects of the virus. 
Yoon et al. (15) demonstrated that the stock of M variant EMC virus is 
composed of at least two separate strains, one a diabetogenic variant and the 
other a nondiabetogenic variant. The variants were separated by plaque 
purification. The range of ability of the different isolates to cause diabetes was 
found to be continuous between 100% and 0%. This could mean that there 
were many variants in the original virus stock, each with a different degree of 
ability to cause diabetes. Alternatively, it could mean that each plaque isolate 
is either a pure isolate of a single variant (either diabetogenic or 
nondiabetogenic) or a particular mix of the two variants which gives the range 
of variation seen. Two plaque isolates were selected, one of which gave 0% 
diabetes when injected into mice (the B variant) and one which induced 
diabetes in 1 00% of the injected mice (the D variant) . When the B and D 
variants were mixed together at B:D ratios of 1, 9, and 99 and injected into 
susceptible mice, diabetes developed in 60%, 11%, and 0% of the mice, 
respectively (15). The investigators expressed confidence in the stability of 
the properties of these two variants since, unlike the M variant stock, repeated 
passage in secondary mouse embryo cells did not cause the D variant to lose 
the capacity to produce diabetes in mice. 
It now seems evident that the diabetogenic nature of the D variant 
depends upon the type of cells in which it is grown. Giron et al. (14) found that 
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the D variant continues to be diabetogenic when grown in L-929 (L) cells , a 
mouse-derived line, while a single passage of the virus in baby hamster 
kidney (BHK-21) cells completely eliminates the diabetogenic ability of the 
virus. The diabetogenic ability of the D variant is fully restored by a single 
passage in a human cancer cell line (He La), but not by a single passage in L 
cells. Therefore, Giron et al. (14) suggested that the D variant, like the M 
variant from which it was isolated, either consists of more than one distinct 
virus or is relatively unstable and some of its properties are easily altered 
during replication in certain cell types. 
Recently Kruppenbacher et al. (62) reported that they were able to take 
the EMC-D variant supplied by Yoon and isolate a non-diabetogenic variant 
by further plaque purification. The D variant could have been in a continual 
mutation mode away from the diabetogenic variant, or the D variant as 
isolated by Yoon and his colleagues could have been an impure virus stock. 
Physical and chemical differences of EMC virus variants. The only 
differences noted so far between EMC-D and EMC-8 virus variants are 1) 
their diabetogenic abilities (15, 63), 2) their relative ability to induce production 
of interferon (IFN) in cell culture or in mice (although both variants are equally 
sensitive to inhibition by IFN) (15), 3) the plaque size in L cells (64), and 4) at 
least one oligonucleotide in the fingerprinting pattern of the T1-digested RNAs 
from the two variants (65, 63). Hybridization and thermal elution profiles of the 
RNAs from the two variants failed to demonstrate any differences, but the 
fingerprint of the T1-digested RNA of the B variant was missing at least one 
oligonucleotide, 20 to 25 nucleotides long, which was present in the digest of 
the O-varian! RNA. Four of the structural proteins (alpha, beta, gamma, and 
delta) of the two variants migrate identically on SDS-PAGE, with a pattern 
I• similar to that already known for EMC virus capsid proteins. No differences in 
II 
1: 
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the sensitivity to different pH values, salt concentrations, ultraviolet irradiation 
or temperature, as measured by infectivity of the viruses , could be found (65). 
Host Regulated Factors Involved in Resistance or 
Susceptibility to EMC Virus-Induced Diabetes Mellitus. Effect of 
genetics. The resistance of certain mouse strains to induction of diabetes by 
infection with EMC virus was early proposed to be due to the genetic traits of 
the resistant mice (66) . The inherited trait for resistance was said by Yoon 
and Notkins (67) to be due to resistance of the beta cells of the pancreas to 
both infection by, and production of, EMC virus. They found that the beta cells 
isolated from resistant strains of mice and grown in vitro had lower infection 
percentages and produced a less infectious virus than did the beta cells from 
sensitive strains of mice. In contrast, EMC virus replicated equally well in 
primary embryo or kidney cell cultures from susceptible or resistant strains of 
mice. They concluded that the development of EMC virus-induced diabetes is 
related to genetically determined host differences which affect the ability of the 
virus to infect beta cells. The same group of investigators (68) demonstrated 
that EMC virus selectively binds in vitro to the beta cells derived from a 
susceptible strain of mice as compared to the beta cells from a resistant strain 
of mice. They concluded that genetically inherited viral receptors cause the 
differences seen in susceptibility among mouse strains. 
Ross et al. (69) and Yoon et al. (70) had shown in earlier studies that 
when mice were infected with EMC-M virus, some strains of mice were 
susceptible and other strains were resistant to EMC virus-induced diabetes. 
When susceptible mice were crossed with resistant mice, the F1 progeny 
were resistant to the diabetogenic effects of the virus. However, more than 
20% of the F2 offspring developed diabetes when infected by the virus. The 
backcross of the F1 progeny to the resistant parents gave offspring which were 
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also resistant. In contrast, when the F1 progeny were backcrossed to the 
susceptible parents, approximately one-half of the offspring were susceptible 
(71 ). The authors concluded that these data are consistent with theories of 
Mendelian inheritance, and that susceptibility to EMC virus-induced diabetes 
is controlled by a single locus. 
Dafoe et al. (72) performed an experiment in which male F1 hybrids 
from a cross between resistant and susceptible strains of mice were induced 
to diabetes signs by chemical means. The diabetic hybrids then received 
pancreatic transplants from neonates of either the resistant or the susceptible 
parental strains of mice. Encephalomyocarditis virus was injected into these 
mice, into sex- and age-matched untreated F1 hybrids, and into each parental 
strain . The parental strains were either susceptible or resistant to the 
diabetogenic effects of EMC infection, as expected. The untreated F1 hybrids 
were intermediate in susceptibility, while the F1 hybrids with transplants were 
also intermediate in susceptibility , regardless of source of the pancreatic 
transplant. These results indicate that host factors are more important than are 
inherited pancreatic factors in determining susceptibility to EMC-induced 
diabetes. 
Effect of hormones and age. Testosterone is one host factor which 
appears to be important in the determination of mouse susceptibility to virus-
induced diabetes. Morrow et al. (73) found that intact male DBA/2 mice (sham 
operated) and male castrates treated with testosterone and infected with the M 
variant of EMC virus had pancreatic insulin concentrations that dropped 
precipitously to 10% of control values with concomitant hyperglycemia. 
Untreated castrates failed to develop hyperglycemia, although the insulin 
content of the pancreas dropped somewhat in these infected animals. Equal 
amounts of viral antigen were demonstrated in beta cells of untreated 
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castrates and those of the other mice. 
Testosterone is not a determining factor in diabetogenic susceptibility in 
all strains of mice, according to Giron and Patterson (74). They found that 
testosterone-treated ICR Swiss female mice, normally resistant to EMC virus-
induced diabetes, were just as susceptible to diabetes induction as male mice 
when infected with the D variant of EMC virus. In contrast, testosterone-
treated DBA/2J female mice were not susceptible to the virus. Other steroid 
hormones (estrone, cortisone , and progesterone) were not effective in 
increasing the susceptibility of ICR Swiss female mice to EMC virus 
diabetogenicity. 
Giron et al. (75) have also found that age of the recipient mice largely 
determines their susceptibility to the diabetogenic effects of EMC-D virus. ICR 
Swiss mice younger than 7 weeks developed lethal encephalitis when 
infected with the D variant of EMC virus, while those older than 7 weeks 
developed diabetes. Testosterone injections enhanced the susceptibility of 
the young mice to the diabetogenic effects of the virus . On the other hand, 
testosterone had no effect on the susceptibility of 9-week-old mice to EMC-D 
virus. It is not clear at this time why the EMC-0 virus loses the ability to infect 
the central nervous system of older mice. 
Effect of interferon. Yoon et al. (15) speculated that differences in IFN 
stimulating ability of the two EMC virus variants could account for the 
difference in diabetogenic potential. The B variant stimulates normal levels of 
IFN while the D variant stimulates little or no IFN production either in cell 
culture or in mice. On the other hand, Giron et al. (14) found that the ability of 
the virus to induce interferon in cell culture had no bearing on whether or not 
the virus pool would retain its diabetogenic characteristics . Recently, Yoon et 
al. (16) repeated their claim that the IFN system is an important determinant in 
18 
the outcome of EMC virus-induced diabetes in mice. They reported that 
repeated administration of IFN or an IFN inducer reduced EMC-D virus-
induced diabetes in mice, while a single treatment with either IFN or its 
inducer had no effect. They also found that treating mice with antibody to 
murine IFN allowed development of mild signs of diabetes in those mice 
injected with the B variant of EMC virus. 
The host strain of mouse influences whether or not IFN, or a variety of 
IFN inducers, inhibit the diabetogenic effect of EMC-D virus. The diabetogenic 
effect of EMC-D vi rus in SWR/J mice was blocked by either 13-IFN or a variety 
of IFN inducers, but the effect was not blocked in ICR Swiss mice by the same 
treatments (17) . The authors implied that in ICR Swiss mice, 13-IFN and the 
IFN produced in response to the inducers poly I:C, pyran , endotoxin , or 
tilorone either do not reach the beta cells of the pancreas, or the beta cells are 
not sensitive to the protective action of IFN. The same group of investigators 
(18) found that when 13-(actually a mix of 13- and a-) or y-IFN was 
administered to adult male ICR Swiss mice four days after infection with EMC-
D virus, the frequency and severity of diabetes signs were increased. In 
addition , the diabetic state was induced in the resistant C57BU6 strain of mice 
under the same conditions. The IFN preparations were given after the acute 
stage of infection, but prior to the onset of insulitis (mononuclear cellular 
infiltration of pancreatic islets) . They concluded that under certain conditions, 
the diabetic state is exacerbated and the normal course of EMC-D virus 
infection in mice is altered by IFN. 
Effect of immune system capabilities. The cellular immune system of 
mice must be functional in order for EMC virus to cause diabetes in infected 
animals. However, the humoral immune system functionality seems to be of 
little consequence (20). Buschard et al. (19) found that the EMC-M strain of 
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virus was unable to induce diabetes in athymic (nu/nu) mice, but heterozygous 
littermates (+/nu) and normal mice of the background strain C57BI/6 
developed diabetes mellitus. 
Immunosuppression of DBA/2 mice with the cyclophosphamide 
derivative Asta 5122 significantly increased the mean value of blood glucose 
levels compared to the positive controls, even though the percentage of 
diabetic animals (88%) was the same in both groups. In contrast, X-irradiation 
(500 R) caused a significant inhibition of the appearance of diabetes in the 
EMC-M virus infected mice. Neither chemical immunosuppression without 
viral infection nor X-irradiation alone caused diabetes in the mice. The 
irradiated mice infected with virus did not have insulitis , but the chemically 
treated mice with virus had a high incidence of insulitis (20). 
In the study of Buschard et al. (19), EMC virus was isolated from all 
inoculated animals. They concluded , "it is the response of the thymus-
dependent lymphocyte system evoked by the virus rather than the virus itself 
that leads to damage to the insulin producing cell" (19, p. 299). The same 
group (76) extended their investigations and found that the M strain of EMC 
virus also did not cause diabetes in athymic nude mice of BALB/c origin. In 
contrast, 36% of normal mice developed diabetes when infected with EMC-D 
virus and 93% of the infected normal mice, but none of the nude mice , 
developed paresis of one or more legs. Virus could be isolated in abundant 
amounts from the pancreas and heart of all virus-inoculated mice, including 
the non-diabetic nude mice. Although the thymus-dependent immune system 
seemed important in this model , the primary mechanism for affecting the islet 
beta cells was not a massive lymphocytic infiltration in the islets. 
Virus replication in various tissues. Gould et al. (64) reported 
differences in the replication of the D and B variants of EMC virus in organs of 
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male ICR Swiss mice. The D variant replicated in the spleen, pancreas, heart, 
lung, and intestines of the mice but EMC-B virus replication was limited to the 
spleen and pancreas. The EMC-B virus strain interfered with the replication of 
EMC-D virus in each of the tissues examined. Insulin levels were initially 
increased by both viruses, but by 4 days postinfection, insulin levels were 
either normal or undetectable in the EMC-D virus-infected mice and were 
dramatically elevated in those mice infected with the B variant. The 
concentration of the D variant was much greater in the spleen than in the 
pancreas of mice with normal glucose tolerance test (GTT) results but the 
relative concentrations of virus were reversed in the 2 tissues of mice with 
abnormal GTT results. The D variant replicated, but to a very limited extent, in 
the heart, lung, and intestinal tissues. Even though the B variant did not 
replicate in these tissues, it still managed to block the multiplication of EMC-D 
virus. ICR Swiss mice were not protected against EMC-D virus-induced 
diabetes by IFN injections; therefore, IFN activity was not the mechanism of 
protection when EMC-B virus was used in these mice. 
Immunohistochemical Techniques. lmmunoperoxidase staining. 
The enzyme horseradish peroxidase (HAP), of molecular weight 40,000, is 
employed in the immunoperoxidase technique as a marker for identification of 
antibodies or antigens at both the cellular and subcellular levels. interaction 
of horseradish peroxidase with certain substrates produces insoluble reaction 
products that can be demonstrated by both light and electron microscopy (77). 
Avrameas and Uriel (78) and Nakane and Pierce (79) were pioneer 
investigators of this method. They proposed independently that enzymes be 
used in the place of fluorochromes as labels for antibodies. 
Disadvantages of immunofluorescence that immunoperoxidase 
staining overcomes include quick fading of fluorescence preparations, the 
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requirement of photography to provide permanent results, limited resolution of 
the fluorescence microscope, nonadaptability of fluorescence to electron 
microscopy, inability to use counterstains, and the inability to use paraffin- or 
resin-embedded sections to perform retrospective studies on stored blocks 
from past years. 
Disadvantages of immunoperoxidase staining include 1) the 
demonstration of relatively minute positively staining areas is limited by the 
light microscope's resolution , 2) endogenous peroxidase, which causes 
nonspecific staining, may not be completely eliminated from the tissue under 
investigation, and 3) products resulting from the enzyme reaction may diffuse 
away from the area where antigen is localized (77). 
Mukai and Rosai (80) applied immunoperoxidase techniques to 
histochemical staining for diagnosis in surgical pathology. This technique has 
greatly improved the diagnostic capabilities of the surgical pathologist. 
Peroxidase-antiperoxidase technique. Sternberger et al. (81) 
developed a peroxidase-antiperoxidase (PAP) method that allowed use of 
unlabeled antibody, thus overcoming a disadvantage of the original 
peroxidase-labeled primary antibody technique in which it was necessary to 
label each antibody specificity and individually. The same PAP complex may 
be used for many different unlabeled antibody specificities. 
Avidin-biotin-peroxidase complex technique. The avidin-biotin-
peroxidase complex (ABC) technique, introduced by Hsu et al. (82, 83), is a 
major advance. This method allows use of highly diluted antibody 
preparations previously only used in radioimmunoassay techniques. The 
ABC procedure employs primary antibody without label, secondary antibody 
labeled with biotin, a low molecular weight (244 daltons) vitamin, and a 
preformed avidin-biotinylated horseradish peroxidase complex. Avidin (from 
22 
egg white) is a glycoprotein of molecular weight 68,000. It has an extremely 
high affinity (Kd=1 o·15 M-1) for biotin which leads to an essentially irreversible 
union , in contrast to reversible antigen-antibody reactions. To stain by this 
method, the tissue section is incubated with a primary antibody specific for the 
antigen in question and then biotinylated secondary antibody is applied. This 
is followed by exposure to the ABC complex which binds very tightly to the 
biotin of the secondary antibody. Visualization is accomplished by incubation 
in a solution of peroxidase substrate to form an insoluble pigment at the site of 
the peroxidase enzyme. Avidin has 4 separate binding sites for biotin . When 
it is incubated, in excess, with biotin-peroxidase molecules, a large lattice-like 
complex develops which is still capable of binding to other biotin molecules. 
The structure of the complex is unknown , but is bel ieved to consist of 
numerous biotinylated horseradish peroxidase molecules cross-linked by 
avidin to give a three-dimensional structure (84) . 
The ABC staining method is capable of providing multiple molecules of 
the peroxidase enzyme at the site of antigen-antibody reaction, in contrast to 
the PAP method in which an average of only 2.4 molecules of peroxidase can 
be attached to each molecule of tissue antigen (77). Hsu et al. (82 , 83) found 
their ABC method to be 8-40 times more sensitive than the PAP technique. 
This method is also more universal than the PAP technique in that it eliminates 
the necessity of preparing peroxidase-anti-peroxidase complexes in different 
species. There is also no need for excess linking antibody, as in the PAP 
method, because biotin coupled to the secondary antibody serves as the link 
and only a minimum amount is necessary because of the high affinity of the 
biotin-avidin reaction (77). 
Many biological molecules, including enzymes and antibodies, can be 
biotinylated without significant loss of biological activity (85) . 
Unlike directly conjugated enzyme-labelled second antibodies, 
biotinylated second antibody is, essentially, identical in size to the 
immunoglobulin molecule and is therefore able to penetrate tissue 
sections much more readily than its more bulky counterpart . This 
property can prove important in strongly fixed sections and it 
reduces the need for protease treatment of sections. (85, p. 34) 
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Likewise avidin can be conjugated with a wide variety of labels without 
inactivation of activity. Thus, the biotin-avidin system provides a great promise 
of numerous potential applications. However, there are two major problems 
that arise because of the chemical structure and properties of avidin derived 
from egg-white. 1) Avidin is highly positively charged at neutral pH because 
of its isoelectric point, which is approximately ten (86). Staining done at a pH 
near neutrality leads to nonspecific binding of the avidin to negatively charged 
molecules (87) such as nucleic acids or phospholipids, resulting in high 
background labeling. 2) Avidin is a glycoprotein and will thus react with 
biological molecules such as lectins through its carbohydrate moiety (88) . 
Streptavidin, a protein of molecular weight 60,000, isolated from 
Streptomyces avidinii (89), has four high-affinity (Kd=1 o-15 M-1) binding sites 
and may be conjugated with a variety of label molecules in a manner that 
retains activity. The properties of streptavidin are very similar to those of 
avidin . However, in contrast to egg-white avidin, streptavidin has an 
isoelectric point near neutral pH, contains no carbohydrate moieties, and has 
a molecular weight that is 8000 daltons less than avidin (85) . In contrast to 
avidin, streptavidin exhibits little non-specific binding to mast cells, kidney, 
liver, or brain tissue at physiological pH (89, 90). 
Controls. It is absolutely essential that proper controls be included with 
each staining procedure (77). There are two necessary controls : 1) A positive 
control slide which is fixed and embedded in an identical manner to the test 
slides and which is known to contain the antigen in question. This slide is 
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necessary to determine that the reagents are performing properly. 2) A 
negative control slide, with the same characteristics as the positive control 
slide, is essential to show nonspecific staining reactions . This slide has 
primary antibody omitted and nonimmune serum substituted during the 
staining procedure. This control slide permits examination for endogenous 
peroxidase activity as well as nonspecific binding of secondary antibody. 
Substrates. One of the earliest substrates utilized in immune-
peroxidase staining was 3,5'-diaminobenzidine (DAB). The enzyme produces 
an insoluble brown pigment when DAB is the substrate. There is a 
modification of the DAB peroxidase staining to produce a jet blue-black 
pigment [personal communication of Hsu in (77)] . These pigments are 
insoluble in water as well as in organic dehydrating and mounting media. 
Thus, when DAB is used, the slides can be permanently mounted and referred 
to over long periods of time since the pigment also does not fade. This 
substrate has the disadvantage of being a potential carcinogen (77). A 
substrate utilized to avoid the carcinogenic potential of DAB as well as to 
provide a contrasting staining color is 3-amino-9-ethyl-carbazole (AEC). It 
provides a red to brownish-red reaction product which is soluble in organic 
solvents. Thus, aqueous mounting media must be used to mount tissue 
sections when this substrate is used. Some AEC sections fade during storage 
over a period of several months (91, 92). 
CHAPTER Ill 
A NATURAL ROUTE OF INFECTION STUDIED 
IN THE MOUSE MODEL OF DIABETES 
INDUCED BY EMC VIRUS 
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Introduction . Previously published studies on the induction of 
diabetes by EMC virus in mice have used an artificial route, intraperitoneal (ip) 
injection, of the virus. While this means of introducing the virus is certainly 
effective in producing diabetic signs in the mice, it may yield results which are 
somewhat different than those obtained following a natural route of infection. 
This study was carried out in order to determine if a natural route of 
infection, either per os (po) or intranasal (i.n.), by EMC virus would reliably 
produce diabetes in mice. The i.n. route was effective in establishing diabetes 
in mice. It allowed a comparison of diabetic signs obtained following infection 
by the i.n. route to those seen after ip injection of the virus. 
Materials and Methods. Mice. Male and female adult mice of the 
SJUJ strain, a highly inbred strain of white mouse, obtained from The Jackson 
Laboratory (Bar Harbor, ME) were used to begin a small breeding colony in 
our laboratory. This strain of mice was used by Yoon et al. (15) to demonstrate 
different strains of EMC in a stock of M variant EMC virus. Mice of various 
ages were used to determine if there is a relationship between mouse age 
and the diabetogenic potential of the virus. The mice were housed in shoe 
box style cages, fed Wayne Lab Blox and given tap water ad libitum. Ground 
corn cobs were used as bedding. 
Cells. L-cells, a continuous culture of mouse connective tissue cells, 
were obtained from the American Type Culture Collection (ATCC). Rockville, 
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Maryland, as NCTC clone 929 cells and were maintained in growth medium 
which was different from the original medium in wh ich they had been 
developed. For this reason, they are no longer considered to be the NCTC 
clone 929 cells and are thus called L-cells. See the following quote from the 
ATCC Catalogue of Strains II, Fourth Ed., 1983, page 17 (93) , regarding the 
description of this clone of cells. "If the cells are maintained in the original 
medium, they may be considered NCTC clone 929 cells; if grown in other 
media, they may exhibit different properties and should be considered to be 
derivatives or sublines" (93, p.17). The continuous culture of BHK-21 , Syrian 
hamster, Mesocricetus auratus, kidney cells, was purchased from ATCC. 
Medium. Eagle's Minimum Essential Medium (EMEM) with Earle's salts 
and non-essential amino acids (GIBCO, Grand Island, NY), containing 5% 
fetal bovine serum (FBS) (Hyclone Laboratories, Logan, UT), 0.1% NaHC03, 
and without antibiotics was used as growth medium for L-cells. The growth 
medium for BHK-21 cells differed only in that the concentration of FBS was 
increased to 9%. EMEM containing 2% FBS, 0.18% NaHC03 , and 50 llg of 
gentamicin/ml was used as diluent when virus or other material was being 
titered and is referred to as test medium in this study. 
Virus. Two different EMC-D virus preparations, one labeled "EMC-D, 4-
29-82, 100% diabetes" and the other labeled "EMC-D, P-3, 7/80", were kindly 
provided by Dr. J. Yoon of the National Institutes of Health . The one dated 4-
29-82 will be referred to as the '82 virus pool and the other preparation will be 
referred to as the '80 virus pool. The '82 virus pool was passaged in L-cells in 
our laboratory for use in all other experiments. The cells were infected with 
the virus, which was allowed to adsorb for 1 hr, test medium was added, and 
the cells were incubated at 37° C. When the viral cytopathogenic effect (CPE) 
was graded 4 (100% of the cells showing CPE) the cells, with medium and 
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virus , were frozen at -80°C. Later, the cells were allowed to thaw at room 
temperature, with occasional shaking of the ice sheet over the surface on 
which the cells had been growing, in an attempt to suspend all cell material. 
The resulting suspension was homogenized for 30 seconds at the full speed 
setting of a Sorvall® Omni-Mixer (DuPont Co., Newtown , CT) while the 
stainless steel cup was in an ice bath. The homogenate was dispensed to 
freezer vials, labeled, and placed at -80°C. 
Vesicular stomatitis virus (VSV), Indiana strain (ATCC, Rockville, MD), 
was passaged in MA 104 cells in a manner similar to that described for EMC-D 
virus. 
Titration of virus in vitro. Two methods, cell culture infectious dose-50% 
endpoint (CCIDso) and plaque assay, were used in these experiments for in 
vitro virus titrations. These titrations were accomplished in the same cells (Lor 
BHK-21) utilized to conduct other assays in which the virus was used as a 
challenge. 
The CCIDso endpoint was determined by titration in cells grown in 96-
well, flat-bottomed, tissue culture plates (A/S Nunc, Denmark or Corning Glass 
Works, Corning, NY) (96-well microplates) . Cells suspended in growth 
medium were seeded in these sterile plates at 2 x 1 os cells/ml, 0.2 ml/well. 
The plates were wrapped in Saran WrapTM (The Dow Chemical Co., 
Indianapolis, IN) and incubated overnight at 37°C to allow the cells to form 
confluent monolayers. Virus was diluted by serial 1 0-fold dilutions in 
polystyrene, 12 x 75 mm, sterile, snap-cap tubes (Becton Dickenson and Co. , 
Lincoln Park, NJ or EIKay Products , Inc., Shrewsbury, MA) containing test 
medium as diluent. The growth medium was decanted from the plates and the 
diluted virus was placed in specified wells within the plate (0.1 ml/well, 4 
replicate wells/dilution). The plate was wrapped with fresh Saran WrapTM and 
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returned to the 37°C incubator. The CPE resulting from virus growth within the 
cells was graded by microscopic examination after 3 days of incubation. The 
50% endpoint of the titration was determined by the method of Reed and 
Muench (94), considering wells with any degree of CPE within the contained 
cells to be infected, and those wells lacking CPE within the cells to be 
uninfected. 
For plaque assay of virus, L-cells or BHK-21 cells were seeded in 6-
well tissue culture plates (NS Nunc, Denmark) at 2 x 1 os cells/mi. 3 ml /dish. 
The dishes were placed at 3?0C in a humidified atmosphere of 5% C02 , 95% 
air, and the cells were allowed to grow to confluence (2-3 days). The growth 
medium was aspirated from the cells and 0.1 ml of a specified virus dilution (in 
test medium) was placed in the center of the cell sheet in each of 2 wells. The 
virus was allowed to adsorb for one hour at 3?0C with rocking every 15 
minutes to keep the cells moist. The cells were then overlaid with 3 ml of a 
mixture of equal volumes of doubly concentrated test medium and 2% Sea 
Plaque® agarose (FMC Corp., Marine Colloids Div., Rockland, ME) prepared 
in glass distilled water. The medium and agarose were tempered to 37°C 
before mixing. The agarose was allowed to solidify at room temperature and 
the dishes were placed at 37°C. When CPE was evident in the cell sheets (1-
2 days), 1 ml of sterile neutral red in normal saline (one part in 5000 parts) 
was placed in each dish and allowed to penetrate the agarose at 37°C for a 
minimum of 2 hours. The excess neutral red was aspirated and the dishes 
returned to the incubator in the dark. The plaques could usually be counted 3-
4 hours later. 
Mouse interferon activity in L-ee/Is and in BHK-21 cells. Interferon (IFN) 
production was induced in L-cells by exposing 7-day old cell sheets, in tissue 
culture flasks, to a miX1ure of 0. 1 mg/ml DEAE Dextran (Pharmacia, Uppsala, 
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Sweden) and 0.01 mg/ml polyinosinic-polycytidylic acid , sodium salt (poly I:C) 
(Sigma Chemical Co., St. Louis, MO) in test medium lacking serum. The 
mixture was left on the cells at 37°C for 1 hr and then decanted. The cell 
sheets were rinsed 2 times with modified Puck's balanced salt solution . Test 
medium supplemented with 0.2% Primatone® RL, a peptic digest of animal 
tissue (Humko Sheffield Chem., Memphis, TN), was added to the flasks. The 
cells were incubated in this medium at 3?0C for 42 hr to allow production of 
IFN. Medium was collected from the flasks of L-cells, centrifuged to remove 
cells and cell debris, dispensed to vials, and frozen at -aooc for future assay. 
The IFN activity of this preparation was titered by diluting it in test 
medium and assaying it in both L-cells and BHK-21 cells. The assay was 
carried out by placing ten-fold dilutions of the IFN (from undiluted to 1 o-6) on 
18-hour monolayers of cells in 96-well microplates from which the medium 
had been decanted. Each dilution of IFN was placed in 4 replicate wells of the 
plate at 0.1 ml/well. The IFN dilutions (or diluent medium without IFN) were 
incubated on the cells at 37°C for 42 hr before they were decanted from the 
cells, and 0.1 ml of challenge virus was added to each well. Both VSV and 
EMC-D virus, each diluted to the same concentration of 100 CCIDso/0.1 ml, 
were used as challenge virus to titer this IFN preparation in the two cell lines. 
When the virus control cells (those exposed to medium lacking IFN) were 
100% destroyed by the virus, all of the wells in each plate were examined 
microscopically and graded for the ex1ent of development of viral CPE. The 
dilution of sample which provided a 50% endpoint of viral CPE was calculated 
and the inverse of this endpoint was defined as the IFN titer (units/0.1 ml) of 
the sample (95). 
Tests on mouse urine. Clinistix®, Diastix®, and Bili-Labstix® Reagent 
Strips for Urinalysis (Ames Division, Miles Laboratories, Elkhart, IN) were used 
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for analysis of urine samples. Both Clinistix® and Diastix® are plastic strips 
with single reagent areas designed to react with glucose. The reagent area of 
each type of strip contains 2 enzymes, glucose oxidase, which catalyzes the 
formation of gluconic acid and hydrogen peroxide from the oxidation of 
glucose, and peroxidase, which catalyzes the reaction of hydrogen peroxide 
with a chromogen . The Clinistix® reagent area contains the chromogen 
orthotolidine, with which hydrogen peroxide produces colors ranging from 
purple through blue. A potassium iodide chromogen in the Diastix® reagent 
area is oxidized by hydrogen peroxide and peroxidase, to colors ranging from 
green to brown, according to the concentration of peroxide present. Bili-
Labstix® Reagent Strips are plastic strips with 6 separate reagent areas fixed 
to the strip. One of the reagent areas is the same as the Diastix® reagent area 
and is used to quantitate glucose in the urine. The other reagent areas are 
individually designed to detect blood, bilirubin , ketone, protein, and the pH of 
the urine. Detailed instructions provided with each of these products were 
followed carefully in the testing procedure. 
Preparation of mouse plasma samples. Pasteur pipets and 1 ml 
polystyrene centrifuge tubes (Allied Fisher Scientific, Pittsburgh, PA) were 
heparinized by dissolving 4 g of sodium fluoride (Sigma chemical Co., St. 
Louis, MO) in 100 ml of water to which 0.5 g (-170 units/mg) of heparin, 
sodium salt, (Sigma) was added and allowed to dissolve. The heparin-
sodium fluoride solution was drawn into and expelled from the Pasteur pipets 
which were then dried in an incubator. One drop of the heparin-sodium 
fluoride solution was added to each centrifuge tube and the tubes were dried 
in an incubator before use. 
Selected mice were individually anesthetized with ether, the brachial 
artery clipped, and the blood collected in a heparinized Pasteur pipet and 
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transferred to a heparinized centrifuge tube. These samples were centrifuged. 
Plasma was collected from each sample , placed in a labeled freezer vial , and 
stored (-80°C) for future tests. 
Determination of plasma glucose levels. Glucose concentration was 
determined by an enzymatic colorimetric method proposed by Kaston (96) and 
modified by Raabe and Terkildsen (97) . The method is based on the coupled 
enzymatic reactions of glucose oxidase and peroxidase, as in the urine test 
strips ; however, in this case, the chromogen is o-dianisidine. Oxidized o-
dianisidine is brown and this color intensity , measured at 425-475 nm, is 
proportional to the glucose concentration in the sample tested. The procedure 
outlined in Sigma Technical Bulletin #510, provided with the kit , was modified 
as to volumes of sample , enzyme mixture, and color reagent solution to 
facilitate utilization of small amounts of sample in a 96-well flat-bottomed 
tissue culture plate. The results were measured at 450 nm in a microplate 
reader (Bio-Tek Instruments, Winooski , VT). 
Titration of neutralizing antibodies in plasma. Each plasma sample was 
diluted in test medium by preparing a single 1 0-fold dilution (on occasion a 
20- or 50-fold dilution was made if the sample volume was insufficient for a 10-
fold dilution). This dilution tube was heated at 56°C for 30 minutes and then 
serial 2-fold dilutions were made from the initial dilution. Equal volumes (0.5 
ml) of each diluted plasma sample and a virus preparation containing 100 
CCIDso of EMC-0 virus/0.1 ml, were mixed together and incubated at 37°C for 
1 hr in a water bath. Virus control mixtures (0.5 ml of diluent , without mouse 
plasma, and 0.5 ml of the virus preparation) were similarly incubated. One-
tenth ml aliquots of each mixture were placed in each of 3 wells of a 96-well 
microplate containing confluent monolayers of BHK-21 cells. Diluent medium 
(0 .1 ml) without virus or mouse plasma, was placed in each well designated 
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as cell control wells. The cells were incubated at 37°C until all virus control 
wells had a CPE grade of 4 and the cell control wells were all still in very good 
condition (CPE grade of 0). The neutralizing antibody titer of each serum 
preparation was determined by calculating the 50% endpoint by the method of 
Reed and Muench (94). Wells with any degree of CPE were considered to be 
unprotected and those without CPE were considered to be totally protected by 
the antibodies in the plasma. 
Mouse experiments in which infection was by the ip route. The '82 
virus pool was diluted in test medium to obtain approximately 1 x 1 as pfu/0.1 
mi. The '80 virus pool was used undiluted to obtain the approximate same 
concentration of virus. Neither of these viral preparations had been passaged 
in our laboratory prior to use in this experiment. Seven mice received an ip 
injection of 0.1 ml of the '82 virus preparation, 7 mice received an equal 
volume of the '80 virus preparation, and 7 mice received 0.1 ml of diluent 
without virus by the same route. Twelve male and 9 female mice were used in 
the initial experiment. Clinistix® test strips were used each day to test all 
urine samples for glucose spillage (glycosuria) . Glycosuria was first evident 
on day 4 post virus inoculation (p.i.), so 3 mice from each group (control and 2 
virus preparations) were sacrificed for plasma glucose and antibody 
determinations. The remainder of the mice were sacrificed on day 7 p.i. for 
like determinations, except that one of the '80 virus-infected mice died on day 
7 p.i. 
The '82 virus preparation was used to infect L-cells. The virus pool 
obtained from this first L-cell passage was assayed by ip injection of mice to 
determine if cell passage in our laboratory would diminish the diabetogenic 
potential of the virus. All experimental materials and methods were similar to 
those used in the first experiment except for the following : 1) the virus pool 
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was different, as noted above; 2) concentrations of 10, 1 Q2, 1 Q3, 1 Q4, 1 as, and 
1 as pfu of virus/mouse, given by the ip route , were used to determine the 
potency of the virus for diabetogenicity in mice; 3) one mouse from each 
group, given different concentrations of virus, was sacrificed on days 4, 7, 14, 
and 21 to determine levels of plasma glucose and neutralizing antibody; 4) 
several female mice, negative for glycosuria on days 4, 7, and 14, were saved 
until day 21 to determine if additional female mice would develop glycosuria 
when given a longer time period after the virus infection; and 5) Diastix® test 
strips were also used to measure glycosuria on the day of sacrifice if the 
mouse was positive by Clinistix® on that day. 
Selection of a natural route of infection. The L-cell passaged virus was 
introduced to male SJUJ mice by po, and i.n. routes of infection, with the ip 
route of infection used as a control. Five mice were selected for each group, 
but only 4 mice received virus by the i.n. route because one mouse was killed 
by the anesthetic. Five control mice each received 0.1 ml of sterile diluent 
medium by the ip route . The ip injections were given by use of a one ml 
syringe with a 26 gauge needle attached. The po inoculations were 
administered with a 20G-1.5" perlektum® (Popper and Sons, Inc., New Hyde 
Park, NY) intubation needle attached to a one ml syringe. The i.n. virus 
delivery was accomplished by use of a micro-pipetter and micro-pipet tips after 
the mice had been lightly anesthetized with ether. The mice exposed to virus 
by the i.n. route received 50 J..LI of virus which was 5 x 1 Q4 pfu/mouse, instead 
of the 1 x 1 as pfu/mouse received by mice exposed to virus by the ip and po 
routes. On day 6 p.i., all living mice were exsanguinated by clipping the 
brachial artery and collecting blood while the mouse was anesthetized. 
Plasma samples were collected, labeled, and frozen for later testing . Urine 
samples were tested daily for glucose by Clinistix® and by use of Bili-Labstix® 
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on the day of sacrifice. 
Titration of the diabetogenicity of EMC-0 virus in mice inoculated by the 
i.n. route. Male SJUJ mice were inoculated i.n. with virus concentrations 
ranging in 1 0-fold increments from 4 pfu/mouse to 4 x 1 as pfu/mouse. The 
virus was given in 20 Ill aliquots because in the initial experiment, some of the 
mice failed to inhale all of the 50 111 inoculum that was presented. Five mice 
were used for each concentration of virus. Five control mice were each given 
20 Ill of the sterile virus diluent by the i.n. route. Glycosuria was determined 
daily by use of Clinistix® test strips. Diastix® test strips were used daily for 
each mouse previously shown to be positive by Clinistix®. On day 7 p.i., all 
mice were exsanguinated to obtain plasma samples that were frozen for later 
assay. 
Statistical analysis. Statistical analysis on the number of positive 
results/total samples was done by chi square analysis. The Student's t-test 
was used to analyze significance of means obtained from glucose 
measurements. 
Results. Activity of mouse IFN in L-ee/Is and BHK-21 cells. The IFN 
induced by treatment of L-cells with poly I:C was devoid of protective activity 
against either VSV or EMC-D virus in BHK-21 cells, but had good activity 
when assayed against either virus in L-cells. Results of the titration are shown 
in Table 111-1. 
Experiments by the ip infection route. Parameters used as diabetic 
signs in the mice were glycosuria and plasma glucose levels greater than 3 
standard deviations above the mean plasma glucose concentration in the 
uninfected controls. 
Results of Clinistix® testing of the urine of mice injected with EMC-D virus 
IFN 
dilution 
Undilute 
10-1 
10-2 
10-3 
10-4 
No IFN 
TABLE III-I. TITRATION OF MOUSE INTERFERON (IFN) 
IN BHK-21 CELLS AND L-CELLS. 
Percent of cells with vinJs CPE 
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~s Y..S.Y.. i!l · ~s EMC-Q Y..i(US ill · 
BHK-21 Cells L-cells BHK-21 cells L-cells 
100 0 100 0 
100 0 100 0 
100 0 100 0 
100 9 100 81 
100 94 100 100 
100 100 100 100 
which had not yet been passed in tissue culture in our laboratory are summa-
rized in Table III-II. These data represent tests on most of the mice at each day 
indicated; however, since some mice withheld urine at one or more sample 
times, all mice in the experiment were not represented by data at each time 
period. 
All mice with glycosuria on the day of their sacrifice also had plasma 
glucose concentrations greater than 243 mg/1 00 ml, which was 3 standard 
deviations above the mean glucose level of the 7 control mice. The mean of 
the plasma glucose concentrations of the 4 mice with diabetes that were 
sacrificed on day 4 (all males) was 331 mg/1 00 ml, with a range of 273-381 
and a S.D. of 46. The 5 mice with diabetes that were sacrificed on day 7 (3 
males and 2 females) had a mean plasma glucose concentration of 377 
mg/100 ml, with a range of 274-500 and a S.D. of 100. 
The 4 female mice which provided a urine sample on day 4 were 
negative for glycosuria as were all male and female mice sampled previous to 
day 4. Two of 4 female mice tested on day 5 were positive by Clinistix®. They 
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TABLE 111-11. GLYCOSURIA IN MICE INJECTED BY THE ip ROUTE 
WITH 2 EMC-0 VIRUS POOLSa. 
Source of sample Da~s after virus inoculation 
0 2 3 4 5 6 7 
Control mice Of6b 0/6 0/4 Of6C 0/3 0/3 Of4d 
Infected mice 0/12 0/9 0/5 7/12 6/8 6/8 5/7 
Infected males 017 0/5 0/3 718 4/4 4/4 3/3 
Infected females 0/5 0/4 0/2 0/4 2/4 2/4 2/4 
All receiving '82 virus 017 0/4 0/3 3/6e 3/4 3/4 3/4f 
All receiving '80 virus 0/5 0/5 0/2 4/6e 3/4 3/4 2/39 
a Both virus pools were provided by Dr. Yoon and had not been passed in 
our lab prior to use in this experiment. 
b Number positive/number of samples provided. 
c Two males and 1 female were sacrificed. 
d Two males and 2 females were sacrificed. 
e Two positive males and 1 negative female were sacrificed. 
t Two positive males and 2 females (1 positive) were sacrificed. 
9 One positive male and 2 females (1 positive) were sacrificed. 
37 
both remained positive until day 7, when the experiment ended. None of the 
other female mice showed signs of diabetes by either parameter, although all 
mice injected with virus exhibited evidence of infection by development of 
neutralizing antibodies to the virus. The 6 mice which were sacrificed on day 
4 had a mean titer of 322 units of neutralizing antibody/0.1 ml of plasma 
(range: 200-480; 8.0 .=119). The 7 infected mice which were sacrificed on 
day 7 had a mean titer of 1706 units of neutralizing antibody/0.1 ml (range: 
480-4470; 8 .0 .=1334). None of the control mice sacrificed on day 4 or day 7 
p.i., had detectable antibody (1 0 units/0.1 ml was the lower limit of detection). 
Four male mice infected with virus (3 which received the '80 virus 
preparation and 1 infected with the '82 virus pool) developed paralysis of one, 
or both, hind legs. Three of these mice were sacrificed on day 4 p.i. , and the 
remaining mouse was dead on day 7 p.i. 
The '82 EMC-0 virus passed in L-cells also caused diabetes in mice. 
All infected male mice became diabetic, even when as little as 10 pfu of the 
virus was administered ip to the animals. All males except 1 were positive for 
diabetes by Clinistix®, Oiastix®, and plasma glucose. The one exception had 
a plasma glucose concentration well within the control range, although both 
indicators of glycosuria were positive. The total number of infected mice with 
glycosuria varied considerably (Table Jll-111) . All male mice injected with virus 
were glycosuric by day 5 and remained so throughout the experiment. In 
contrast, only 9 of 14 females became glycosuric at any time in the 
experiment, 1 as late as day 7. Two of the female mice had cured of 
glycosuria before they were sacrificed. Therefore, the variation was due to the 
numbers of female mice that developed, or recovered from , glycosuria. All 
female mice that developed glycosuria did so by day 7 p.i. 
TABLE 111-111. GLYCOSURIA IN MICE INJECTED BY THE ip ROUTE 
WITH VIRUS PASSED IN l -CELLS 
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Source of sample Number of days after virus inoculation 
0 4 
Control mice 014a 0/4 
Mice infected with 10 pfu 0/4 0/4 
Mice infected with 1 02 pfu 0/4 2/3 
Mice infected with 103 pfu 0/4 212 
Mice infected with 104 pfu 0/4 2/3 
Mice infected with 1 os pfu 0/4 3/3 
Mice infected with 1 os pfu 0/4 2/3 
All infected mice 0/24 11 /18 
Infected male mice 0/10 5/6d 
Infected female mice 0/14 6/12h 
a Number positive/number of samples obtained. 
b Mouse died on day 18. 
c Mouse died on day 13. 
d Two positive male mice sacrificed. 
e Five positive male mice sacrificed. 
f Three positive male mice sacrificed. 
g All males previously sacrificed. 
7 
0/3 
2/3 
3/3 
2/2 
2/3 
3/3 
2/3 
14/17 
717e 
7/10i 
h Four females sacrificed (3 positive and 1 negative) . 
i One positive female sacrificed. 
k Two positive females sacrificed. 
m Six females sacrificed (1 positive and 5 negative) . 
14 21 
0/2 ob 
1/2 0/1 
1/2 0/1 
1/2 0/1 
1/2 0/1 
2/2 1/1 
0/ 1C 0/1 
6/ 11 1/6 
3/3f 09 
3/8C,k 116m 
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Results of Clinistix® test ing of the urine of the mice did not always agree 
with results of plasma glucose testing . Most discrepancies (3 of 4) occurredin 
female mice (Table III-IV). Results of tests on mice sacrificed on day 21 were 
not included because plasma samples were mistakenly discarded. 
Natural routes of infection. In an experiment to determine if a natural 
route of infection could be used to obtain diabetic signs in SJUJ male mice, 
two natural routes, i.n. and po, were compared to the commonly used ip route. 
As evident in Table 111-V, none of the control mice nor the mice which received 
virus by the po route showed signs of diabetes on any of the sample days. 
One of the mice given virus by the po route died on day 3 p.i., and one which 
received virus by the i.n. route was dead on day 6. One mouse infected by the 
ip route (the one with the lowest plasma glucose level) was near death 
immediately before sacrifice on day 6. Three of 4 mice infected by the ip route 
began showing glycosuria as early as day 4 p.i. and all mice in this group had 
developed high glycosuria, as well as diabetic plasma glucose levels, at the 
time of sacrifice . The mice infected by the i.n. route began spilling glucose 
one day later than those infected ip, with the earliest onset on day 5 p.i. 
However, on day 6 p.i. , all of these mice exhibited high levels of plasma and 
urine glucose similar to those found in the ip-infected mice. In both situations 
(ip and i.n.), the increased positives/total were statistically significant. None of 
the control mice, nor those exposed to virus by the po route, developed 
neutralizing antibody to the virus. However, all mice exposed to the virus by 
either the i.n. or the ip routes developed neutralizing antibody titers greater 
than 200 units/0.1 ml by day 6 p.i. The magnitude of the antibody titers, as 
related to the concentration of plasma glucose present on the day of sacrifice, 
is recorded in Fig . 111-1, along with similar results from other experiments. Little 
correlation could be made between concentration of plasma glucose and 
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TABLE III-IV. COMPARISON OF 3 PARAMETERS USED TO DETERMINE THE DIABETIC 
STATE IN MICE INJECTED BY THE ip ROUTE WITH VIRUS PASSED IN l-CELLS. 
Source of sample Day of sacrifice post-virus inoculation 
Cia Dib PGC Cl Di PG Cl Di PG 
Female, 10 pfu o· o· 196* 
Female, 102 pfu D 5 477 
Female, 103 pfu D 188* 
Female, 104 pfu L o· 302 
Male, 1 os pfu D 5 514 
Male, 1 os pfu D 2 392 
Female, 10 pfu D n.s.d 154* 
Male, 1 02 pfu D 1 186* 
Male, 103 pfu D 5 372 
Male, 1 04 pfu D 5 562 
Male, 1 os pfu D 5 426 
Male, 1 os pfu D 5 412 
Male, 10 pfu D 5 611 
Female, 102 pfu L o· 176* 
Male, 103 pfu D 5 767 
Male, 104 pfu D 5 722 
Female, 105 pfu D 5 385 
a Clinistix® results: O=negative; L=light; M=medium; D=dark. 
b Diastix® results: O=negative; 1 =1 00; 2=250; 3=500; 4=1 000; 5=~2000 
mg/100 mi. 
c Plasma glucose concentration (mg/1 00 ml) . 
d No sample obtained. 
• Non-diabetic result. 
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TABLE 111-V. OIABETOGENICITY OF EMC-0 VIRUS ADMINISTERED BY DIFFERENT 
ROUTES IN MALE SJUJ MICE. 
Qal£S 8f!er ~irus lnQQijlaliQn 
___L. ~ ___..5.._ 
Virus Clinistix Clinistix Clinistix Diastix Plasma gi~JQQSe Neutral. 
inoculation Pas./ Pas./ Pas./ Pas./ Pas. a; Titerb antibody 
route total total total total total titer: 
None 0/3 0/3 0/4 0/5 0/5 151 0 
po 0/3 0/3 0/4 0/4 015 150 0 
i.n. 0/4 0/3 2/3 3/3 3/3 452 3840 
ip 0/4 3/4 2/3 515 5/5 522 2582 
a 2:3 S.D. above the mean plasma glucose cone. of control mice sacrificed 
on day 6. 
b mg/100 ml (mean) . 
c units/0.1 ml (mean). 
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FIG. 111·1 . Scatter graph of the relationship between plasma glucose con· 
centration and antibody titer in mice inoculated with EMC·D virus. 
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antibody titer. The correlation coefficient (R) calculated for the straight line of 
best fit to the data points was 0.04. A table of critical values for the Pearson 
correlation coefficient was used to test the validity of the hypothesis that a 
correlation between concentration of plasma glucose and antibody titers 
existed. The P-value was found to be > 0.05, indicating no statistical 
correlation . 
Results of Bili-Labstix® tests of the urine other than glucose (blood, 
bilirubin , ketone, protein, and pH) were not consistently different between 
control and infected mice and were not done in other experiments. 
Titration of virus by the i.n. route of infection. Results of tests for 
glycosuria and plasma glucose, as well as neutralizing antibody titers of all 
mice exposed i.n. to the virus, are summarized in Table Ill-VI. None of the 
control mice, nor those which received either 4 or 40 pfu of virus, developed 
signs of diabetes or neutralizing antibodies. Only one of five mice which 
received 400 pfu of virus was diabetic during the experiment. This mouse 
exhibited glycosuria for the first time on day 6, was positive for diabetes by 
glycosuria and plasma glucose, and was the only mouse in this group positive 
for neutralizing antibody on day 7. Two of 5 mice which received 4 x 103 pfu 
of virus were not diabetic by any parameter. However, one of these mice had 
a high titer of neutralizing antibody while the other mouse had no neutralizing 
antibody. The other 3 mice in this group developed high levels of urine 
glucose, plasma glucose, and neutralizing antibody. All of the mice inoculated 
with 4 x 104 pfu of virus showed glycosuria at some time during the 
experiment. Two of the mice were negative for glucose in the urine by 
Diastix® on the day of sacrifice , although one of these mice earlier (day 5) had 
a Diastix® reading of 500 mg/1 00 mi. This reading dropped to 250 mg/1 00 ml 
on day 6 and was negative on day 7, even though the Clinistix® reading was 
TABLE Ill-VI. TITRATION OF INTRANASALLY ADMINISTERED EMC-0 VIRUS IN MALE SJUJ MICE. 
pays after virus inoculation 
___a_ 
____.!__ ___.5__ ___6__ 
Virus Clinistix Clinistix Clinistix Clinistix Diastix 
cone. Pos./ Pos./ Pos./ Pos. Pos./ 
(pfu/mouse) total total total total total 
4 0/4 0/5 0/4 0/3 0/5 
4x10 0/5 0/3 0/5 0/3 0/5 
4x102 0/5 0/4 1/4 1/4 1/5 
4x103 0/4 1/4 3/5 1/3 3/5 
4x104 0/5 1/4 4/5 4/5 3/5 
4x105 0/5 1/4 5/5 5/5 5/5 
a ~3 S.D. above the mean plasma glucose cone. of control mice sacrificed on day 7. 
b mg/100 ml (mean). 
c units/0.1 ml (mean). 
Elasrna ghiQQS!l 
Pos.a/ Titerb 
total 
0/5 168 
0/5 196 
1/5 249 
3/5 373 
3/5 374 
5/5 384 
Neutralizing 
antibody 
titer<: 
0 
0 
512 
1278 
3460 
1711 
~ 
~ 
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medium for glucose on the day of sacrifice. The other Diastix®- negative 
mouse had a positive Clinistix® reading (dark) for the first time on the day of 
sacrifice. Neither of the two Diastix®-negative mice had high plasma glucose, 
but the other 3 mice were diabetic by plasma glucose as well as by Diastix® 
on day 7. All of the mice in the group exhibited high neutralizing antibody 
titers in the plasma taken on day 7. The earliest times of glycosuria in this 
group of mice was day 4 (one mouse). Three others began spillage on day 5, 
and the last mouse showed no glycosuria until day 7. All of the mice in the 
group receiving 4 x 1 os pfu of virus were diabetic by both parameters tested. 
One of these mice began spilling glucose in the urine on day 4, and the other 
4 began spilling on day 5. All of these mice also developed neutralizing 
antibody specific to the virus. 
Discussion. The comparative titration of mouse IFN in L-cells and 
BHK-21 cells was carried out in order to identify a cell line which would not 
respond to mouse IFN. A cell line of this type was necessary to insure that 
neutralizing antibody titrations could be performed without interference by 
mouse IFN, which was present in some of the plasma samples to be tested. 
BHK-21 cells served this purpose well. They were very sensitive to infection 
by EMC-D virus and pretreatment with mouse IFN did not alter this sensitivity. 
Thus, the "species specificity" of mouse IFN is valid in this case ; i.e. mouse IFN 
is inactive in cells from the hamster (BHK-21 cells). 
There was no apparent difference in the diabetogenic potential of the 2 
different pools of virus received from Dr. Yoon when studied prior to cell-
culture passage in our laboratory. However, the '80 virus pool caused a few 
more mice to develop central nervous system infections than did the '82 virus 
pool. For this reason , the '82 virus pool was chosen as seed for cell culture 
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passage in our laboratory to prepare vi rus for additional experiments. 
The preparations of EMC-D virus supplied by Dr. Yoon , as well as the 
virus pools prepared in our laboratory in L-cells, were diabetogenic in SJUJ 
mice to the same extent as that previously published by others (14, 15, 18, 62). 
In agreement with previous investigators (74), it was found that this virus 
induced diabetes in a higher percentage of male mice than it did in female 
mice when they were injected with identical amounts of the virus. This was 
apparently due to a hormonal effect, according to the work of Morrow, et al. 
(73) , Giron and Patterson (74), and Giron, et al. (75). Male mice began spilling 
glucose in the urine one day earlier than the female mice, as seen in Table III-
II . In the experiment summarized in Table 111-111, 4 of the male mice were 
glycosuric on day 3, while none of the female mice spilled glucose on that day 
(data not shown) . Others have not reported a difference in time of 
development of diabetes among male and female mice. 
Only four of the published reports (11, 62 , 73, 76) dealing with this 
mouse model of diabetes referred to the measurement of glucose spilled in 
the urine. These reports only briefly mentioned that the investigators had 
tested urine for glucose. No comparisons were made between results of the 
urine- and blood-glucose tests. None of the investigators consistently utilized 
this measurement as an indicator of development of diabetes in the mice. It 
seemed logical that methods developed for, and widely used by, humans for 
demonstration of diabetic symptoms, could also be used to demonstrate 
diabetic signs in mice. Since mice tend to urinate as they are being handled, 
it was decided to investigate the use of commercially prepared indicators of 
glucose in the urine, namely Clinistix® and Diastix® reagent strips. Bili-
Labsti x® were also used in one experiment to determine if other abnormal 
conditions would develop in the urine in the short period of time necessary for 
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the virus to cause diabetes in mice. Lack of abnormal results, other than 
glycosuria, unique to the diabetic mice, as well as the difficulty of collecting 
sufficient urine at the proper time to accomplish all of the tests on each reagent 
strip, precluded use of Bili-Labstix® strips in additional experiments. 
The experiments presented here demonstrate that normal SJUJ mice 
do not spill sufficient glucose in the urine to be detected by reagent strips 
designed to detect glycosuria. A total of 93 control mice were tested for 
glycosuria on a daily basis over periods of time from 4 days to 64 days, and 
none had a positive test. Thus, it was assumed that a positive finding with 
either Clinistix® or Diastix® test strips indicated that the tested animal has had 
some part(s) of its normal glucose control mechanism altered toward 
production of diabetic signs. 
In the experiment in which the '80 and '82 EMC-D pools were 
examined, all of the mice which spilled glucose in the urine, as determined by 
Clinistix® measurement, also had plasma glucose levels which were 
considered to be in the diabetic range. These results suggested that Clinistix® 
testing is in complete agreement with the more cumbersome method of 
measuring glucose levels in the plasma of the mouse. However, in other 
experiments, there were some positive Clinistix® tests of urine from mice 
which had plasma glucose concentrations in the normal control range. These 
results seem contradictory because one would not expect spillage of glucose 
into the urine until after blood glucose levels were above the "renal threshold 
concentration" at which tubular reabsorption of glucose no longer matched the 
filtered load (98). Certainly, one would have expected spillage of glucose into 
the urine once the "threshold concentration" was reached. In cases of such 
contradictory results, virus infection may have altered the active transport 
mechanism of the renal proximal tubular cells so that glucose was spilled into 
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the urine while blood glucose concentration remained within a normal range. 
Alternatively, plasma glucose might have increased to a level sufficient to 
cause a threshold concentration in the proximal tubule for a period of time, 
thus allowing urine in the bladder to contain glucose. However, by the time 
the mouse was sacrificed, the plasma glucose level was back to normal, while 
the urine stored in the bladder still contained measurable glucose. 
Pitts (99) described a clinical condition known as intercapillary 
glomerulo-sclerosis in which glycosuria could be absent despite high plasma 
glucose concentrations . This condition is due to a reduced glomerular 
filtration rate caused by deposition of a mucopolysaccharide-protein complex 
in the glomerular capillary. If the passive glomerular filtration rate is so easily 
affected, the more complicated , active transport mechanism of tubular 
reabsorption could be inhibited greatly by something as pervasive as viral 
infection. 
The Diastix® test strips were not as sensitive in these experiments as 
the Clinistix® strips , but they are designed to be quantitative. Therefore, a 
Diastix® reading would be expected to more closely agree with the results of 
plasma glucose measurements. Either an initial threshold level of glucose or 
a transient threshold level could allow non-reabsorbed glucose to be diluted 
sufficiently in the bladder to give negative, or low, Diastix® readings, even 
though Clinistix® tests were positive. Only a glucose imbalance which had 
increased over a period of time would be sufficient to give high Diastix® 
readings. All test mice had plasma glucose levels greater than 3 S.D. above 
the mean plasma glucose level of control mice when the Diastix® reading of 
their urine was 250 mg/1 00 ml or above. 
Lack of sufficient virus to cause a generalized infection was not the 
reason that some of the mice failed to develop diabetic signs. All mice 
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injected with virus by the ip route developed virus-specific antibody in the 
plasma, even as early as 4 days after the virus had been injected, and when 
only 10 pfu of virus was given to each mouse. Not all of these mice became 
diabetic. 
Experiments by the i.n. route of infection demonstrated that all mice 
which failed to develop neutralizing antibody also failed to show diabetic 
signs. One mouse, although given the high dose of 4000 pfu of virus, failed to 
develop either circulating antibody or diabetes. Four of the 5 mice given 400 
pfu of virus were similarly negative in both categories . Thus, either some 
specific site must be infected by the virus , or some specific set of 
infection/resistance parameters must be achieved, in order to trigger 
development of diabetic signs. During the development of the particular set of 
circumstances necessary for triggering diabetic signs, the virus must achieve 
an infection that is sufficiently generalized to initiate antibody production. 
However, the magnitude of virus neutralizing antibody production has a low 
correlation with the concentration of glucose in the plasma, indicating that the 
neutralizing antibody alone is not responsible for high glucose levels. 
It was clear from the results of these experiments that mice can be in a 
transient state of glucose imbalance to the extent that they spill glucose into 
the urine for a period of time, and then return to normal conditions. Female 
mice appeared bet1er able than male mice to resist and/or overcome the 
diabetogenic effect of this virus. However, a few male mice, at least those 
exposed to a low to intermediate dosage of the virus, were sometimes also 
able to overcome the diabetogenic effect of EMC-D virus. In these cases, the 
males also had transient glycosuria, and seemed to return to normal glucose 
balance. The mechanisms by which some individuals were able to 
successfully resist the diabetogenicity of this virus is not known. One purpose 
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of this study was to provide an improved model to be used in the 
determination of these resistance mechanisms. 
The i.n. route of infection is an excellent natural route of infection for this 
virus/mouse model of diabetes development. When this route of infection is 
used, the diabetic signs generally begin to appear a day later than when 
infection is by the ip route . However, when a high titer (~1 os pfu) of virus is 
used to infect males, the ultimate percentage of mice induced to develop 
diabetic signs is essentially the same whether the i.n. or the ip route of 
infection is used. On the other hand, the po route of infection was completely 
ineffective for induction of diabetic signs in the mice. In fact, the mice were 
totally resistant to generalized infection as determined by a complete lack of 
development of neutralizing antibody when a high concentration of the virus 
(1 os pfu/mouse) was introduced by this route. 
It was surprising that the po route of introduction of EMC virus was 
ineffective in establishing an infection in the mice. This virus is classified as a 
mouse enterovirus and is resistant to low pH , although somewhat conflicting 
reports as to the extent of this resistance have been published (12 , 100, 101 ). 
Because of its classification as an enterovirus, EMC virus would be expected 
to be infectious by the po route. In fact, according to one author (1 02, p.565), 
"Occasionally, mice can be infected with virus-contaminated drinking water.", 
and, "Contact transmission among cotton rats and infection by feeding in the 
case of albino mice have been demonstrated" (1 02, p.567). Others have 
reported that several species of monkeys have been infected by the po route 
(12). Craighead et al. (1 03) have infected swine with EMC virus by the oral 
route. It is possible that selection of the diabetogenic strain of the virus also 
eliminates the virus strain which is resistant to low pH. However, this 
possibility, as well as the possibility that the wild-type virus is not infective by 
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the po route of infection, has not been tested. 
The diabetogenicity of the virus is more dose responsive when given by 
the i.n. route than when given by the ip route . This could be due to the fact that 
virus introduced by the artificial route of infection circumvents some of the 
mechanisms of natural resistance to infection encountered in the natural route 
of infection . This conclusion is supported by study of neutralizing antibody 
data obtained following i.n. exposure to different concentrations of EMC-D 
virus. All of the mice that received less than 400 pfu of virus were able to 
eliminate the virus before it was able to stimulate antibody production, i.e. 
before a generalized infection was established. Four of the 5 mice that 
received 400 pfu of virus were able to eliminate the virus prior to 
establishment of sufficient infection to induce circulating antibody. Even when 
virus was given at a concentration of 4 x 103 pfu/mouse, 1 of the 5 mice 
escaped infection sufficient to produce detectable antibodies in the plasma. 
Conversely, when virus was given by the ip route , all mice developed 
neutralizing antibodies, even when as little as 1 0 pfu of virus was given. 
Titration of the diabetogenicity of the virus in male mice revealed that 
low doses of virus, similar to those which caused diabetic signs when given by 
the ip route, were ineffective when introduced by the i.n. route. However, with 
increasing concentrations of virus, the percentage of diabetic mice increased 
to 100%. With the i.n. infection, diabetogenicity is related to the dosage of 
virus administered. Thus, adjustments of the virus concentration should allow 
one to more fully study the differences in host resistance occurring in mice that 
are or are not susceptible to the diabetogenic aspects of the virus. This should 
be possible, even if the virus strain and dosage are identical in each case. 
Conversely, when the virus causes diabetic signs in 100% of the mice, control 
mice for study of resistance factors involved in permitting or prohibiting the 
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diabetic state must either be non-infected mice or mice infected by a non-
diabetogenic virus. Thus, the i.n. route of infection by intermediate 
concentrations of this virus may enable one to differentiate the quirks in 
resistance mechanisms that allow the virus to establish a diabetic condition in 
the mouse. 
Conclusions. Mouse IFN was not active in BHK-21 cells. Therefore, 
the neutralizing antibody titers determined in these cells were not affected by 
the presence of IFN in the mouse plasma. 
Measurement of glucose in the urine of mice by use of Clinistix® and 
Diastix® reagent strips provided a reliable method to determine if the mice 
were diabetic or not. The method was easily and quickly accomplished 
without harm or pain to the mice. The only deficiency in the method was that 
sometimes individual mice failed to provide a sample of urine for testing . 
A natural route of infection, the intranasal route, was found to be 
reliable in allowing the EMC-D virus to cause a diabetogenic infection in male 
SJUJ mice. The i.n. route of infection, unlike the ip route, provided a wide 
range of dose response for the diabetogenicity of EMC-D virus. When mice 
were given either 4 or 40 pfu of virus i.n., they remained free of diabetes and 
also did not develop neutralizing antibody. Twenty percent of the mice 
developed diabetes when given 4 x 102 pfu of the virus. When 4 x 1 Q3 pfu of 
virus was given i.n., 60% of the mice developed diabetes. Half of those 
without diabetes at this concentration of virus, also lacked antibody specific for 
the virus. All of the male SJUJ mice given ~4 x 104 pfu of EMC-D virus i.n. 
developed diabetes. As little as 10 pfu of this vi nus, given to male SJUJ mice 
by the ip route, caused 100% of the mice to become diabetic. All mice which 
developed diabetes, regardless of the route of infection, also produced 
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neutralizing antibody to the virus. 
When virus was given by the po route, no signs of infection were 
observed. The mice did not develop diabetes nor did they produce 
neutralizing antibody. 
Some mice became temporarily diabetic by the EMC-D virus infection 
and then spontaneously recovered. The mechanism by which this recovery 
occurred is unknown. 
CHAPTER IV 
EFFECTS OF PURIFICATION ON THE 
DIABETOGENICITY OF 
EMC-D VIRUS 
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Introduction. Craighead and Mclane (11) published the first report of 
a strain of encephalomyocarditis (EMC) virus causing diabetic signs in mice. 
These investigators named the diabetogenic strain of EMC virus, which they 
had isolated from the heart tissue of infected mice, the M-variant ; M standing 
for myocardium. More recently, Yoon et al. (15) were able to purify several 
strains of EMC virus from the M-variant by plaquing techniques. The purified 
strains seemed to differ only by their relative ability to cause diabetes in a 
particular strain of mouse. Some of the plaque isolates had no ability to cause 
diabetes in the mice, some had the ability to cause 100% of infected mice to 
develop diabetes, and other isolates were intermediate in their diabetogenic 
ability. 
Yoon's group expressed confidence that their D variant (EMC-D), 
diabetogenic in 1 00% of the male mice infected by it, was stable in this 
property, since they had passaged the virus variant repeatedly in secondary 
mouse embryo cells without diminishing its diabetogenic ability. However, 
Giron et al. (14) suggested that the D variant consists of either more than one 
distinct virus strain, or that it is a relatively unstable strain, the properties of 
which are easily altered during replication in various cell types. They came to 
this conclusion after observing that EMC-D virus displayed different degrees of 
diabetogenicity according to the type of cells from which it was harvested. 
The altered diabetogenicity observed by Giron et al. could have been 
55 
due to cell material in the crude virus preparations used in the experiments. 
Perhaps it is not the virus alone, but a combination of certain materials from 
th e cell culture along with the virus, that is responsible for producing the 
diabetic state. Alternatively, materials from certain cell cultures may mask the 
diabetogenic ability of the virus. At this time, it is only known that certain 
strains of EMC virus appear to vary in their ability to cause diabetes in mice 
according to the type of cells in which the virus was prepared. 
The purpose of this investigation was to determine if purification of 
EMC-D virus would alter its diabetogenic characteristics. 
Materials and Methods. Virus. EMC-D virus was prepared by a 
single passage in L-cells as outlined in the materials and methods section of 
Chapter Ill. A few small aliquots of the crude virus preparation were 
dispensed to vials and frozen for later comparative assays. The remainder of 
the virus pool was purified as outlined in the next section. 
Virus purification. Sixty-seven ml of ice-cold Freon 113 was added to 
250 ml of the homogenized virus pool in a 400 ml stainless steel Sorvall® 
Omni-Mixer cup (DuPont Co. , Newtown, CT) , and the mixture was 
homogenized for one min at 8,000-10,000 rpm in an ice bath. The 
homogenate was transferred to Nalgene® #3119-0050 polyallomer 50 ml 
screw cap tubes (American Scientific Products, Sunnyvale, CA) which had 
been sterilized in the autoclave. The tubes were placed in the SS-34 rotor of 
the RC-2-8 centrifuge (Ivan Sorvall, Inc., Norwalk, CT) and centrifuged at 
2,000 rpm for 10 min. at 0°C. 
The clear red supernatant liquid was carefully decanted from each 
centrifuge tube and collected in a sterile 1,000 ml Erlenmeyer flask. This 
resulting virus pool was mixed and placed in an ice bath. A few 0.2 ml 
aliquots of the pool were dispensed to freezer vials and placed at -sooc for 
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later assay. 
The pH of the Freon extracted pool was 7.8. After adding 3.5 ml of 10% 
acetic acid in an ice bath , the pH was 4.8. Very fine , white , hair-like particles 
began to appear in the bright yellow liquid after about 5 min. After 
approximately 30 min., some of the liquid was poured into 2 sterile Nalgene 
polyallomer tubes and these were centrifuged in the SS-34 rotor of the Sorvall 
RC-2-B centrifuge at 4,000 rpm for 10 min. at 4°C. The supernatant liquid was 
decanted into a sterile tissue culture flask (Corning Glass Works, Corning, NY) 
and the above centrifugation step was repeated after more of the acidified 
virus preparation was decanted into the tubes . These two steps were 
repeated until all of the virus preparation had been centrifuged. After the final 
centrifugation , a small white button could be seen in one of the centrifuge 
tubes before the supernatant liquid was decanted. Both centrifuge tubes were 
washed with 0.5 ml of acidic medium (pH 4.5-5.0) in an attempt to resuspend 
the small pellets, and then washed 5 times with 1 ml volumes of sterile PBS. 
All washings were collected in a sterile stainless steel micro Omni-Mixer cup 
and homogenized at full speed for 1 min. in an ice bath. Samples of this acid 
precipitate (A.P.) virus homogenate were stored at -8ooc for future assay. 
One ml of sterile-filtered CsCI solution (895.3 mg/ml) was pipetted into 
each of 6 centrifuge tubes (Beckman® #331370, cellulose nitrate, Beckman 
Instruments, Fullerton, CA). One ml of sterile PBS was placed in tube #6 and 
1.0 ml of the A.P. virus homogenate was placed in each of the other 5 tubes. 
Approximately 11 ml of Nujol® Laxative Extra Heavy Mineral Oil (Plough, Inc., 
Memphis, TN) was placed in each of the 6 tubes. The tubes were centrifuged 
in the Beckman® L8-70 ultracentrifuge (Beckman Instruments) at 14°C, 25,000 
rpm, slow acceleration, brake off, for 16.5 hours with tubes in their respectively 
numbered buckets of the SW41 rotor. After centrifugation, fractions were 
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obtained by collecting single drops from a hole punctured in the bottom of 
each tube. The fractions were co llected from tube #6 first, and then from each 
of the other tubes in the order #1 through #5. A single drop was collected in 
each of the 1.0 ml non-sterile polystyrene centrifuge tubes (Fisher Scientific, 
Pittsburgh, PA) used to collect from tube #6. The same amount was collected 
in each of the sterile Fisher #05-407-5 centrifuge tubes used to collect from 
tube #1 . One ml polystyrene centrifuge tubes were used to collect single 
drops from tube #2. The single drops collected from each of tubes #3 through 
#5 were pooled in sterile Fisher #05-407-5 centrifuge tubes . 
Refractive indices of each sample collected from tube #6 were 
measured by use of a Bausch and Lomb refractometer (Fisher Scientific). A 
Haake type F constant temperature water bath (American Scientific Products, 
Sunnyvale, CA) was used to maintain a uniform 25°C temperature on the 
refractometer glass plate. The density of each sample was calculated from the 
refractive indices by use of the formula of Bruner and Vinograd (1 04) : p25oc = 
1 0.2402 TJ o2soc - 12.6483 for densities between 1.00 and 1.37 g/cm3, where 
p25oc =density at 25°C and TJo25oc = refractive index measurement at 25°C. 
The refractive index was corrected for the PBS in the CsCI samples before the 
density was calculated. 
Tubes containing fractions collected from centrifuge tubes #1 through 
#5 were capped and placed at -sooc for storage until assays could be 
performed. 
Protein assay. Protein in each sample was assayed by the Bio-Rad 
Protein Assay procedure (Bio-Rad Laboratories, Richmond, CA). Bovine 
plasma gamma globulin was used as a protein standard (Bio-Rad Protein 
Assay Standard 1) . 
Medium. The same types of cell culture medium as those described in 
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the materials and methods section of Chapter Ill were used in these 
experiments. 
Cells. See the materials and methods section of Chapter Ill. 
Virus assay. Virus was assayed by the plaque assay method outlined 
in Chapter Ill, materials and methods section. 
Mice. Mice were used as described in the materials and methods 
section of Chapter Ill. 
Neutralizing antibody assay. Sera of mice were assayed for 
neutralizing antibody as explained in the materials and methods section of 
Chapter Ill. 
Experiments comparing diabetogenicity of crude and purified virus 
pools. Male mice received either 4 x 1 Q3, 4 x 1 Q4, or 4 x 1 as pfu of crude or of 
purified virus by the intranasal (i.n.) route while they were lightly anesthetized 
by ether. In the first experiment, female mice were included to determine if 
they would respond to purified virus differently than the male mice. The 
females received only the 4 x 1 Q4 pfu dosage from each virus pool by the i.n. 
route of inoculation. All mice in this experiment were sacrificed 7 days after 
receiving virus in order to determine plasma glucose and neutralizing 
antibody levels. 
A second experiment was run to determine if additional mice would 
develop diabetes when allowed a longer period of time for development of the 
disease. Both crude and purified virus preparations were used for infection to 
determine if one would be more diabetogenic than the other. The rate of 
death and number of diabetes cures were also observed for differences 
between crude and purified virus. Mouse sacrifice was delayed from the 7 
days of the first experiment to either 9 or 21 days to allow more time for 
development of diabetes. Up to 10 mice from each group that had glycosuria 
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on day 9 p.i., or that had demonstrated a remission of glycosuria by day 9, 
were selected for sacrifice on that day. The other mice in each group were 
retained for obseNation over the full 21 days. A 1 0-fold higher dosage of virus 
was given to females in this experiment to determine if increased virus would 
cause more females to become diabetic. 
The mice of both experiments were monitored daily for glycosuria by 
use of Clinistix® (Ames Div. , Miles Laboratories, Inc., Elkhart, IN). After they 
were positive by this test , Diastix® (Ames) test strips were used in order to 
obtain quantitative results. 
Bleeding and plasma sample collection. Bleeding and plasma sample 
collection techniques were the same as those in the materials and methods 
section of Chapter Ill. The plasma samples were frozen (-80°C) and analyzed 
later for glucose and neutralizing antibody, as outlined in the materials and 
methods section of Chapter Ill. 
Results. Virus purification. The infectious virus recovered in the 
pooled fractions from density gradient tubes 3, 4, and 5 is shown in Fig. IV-1 a. 
The virus recovered in each fraction from density gradient tube 2 is shown in 
Fig . IV-1 b along with the density of corresponding fractions recovered from 
density gradient tube 6. 
At each step of the purification procedure, the percentage recovery of 
plaque forming units of virus was compared to the percentage recovery of total 
protein to obtain a purification index (1 05). These results for sample #25 of 
pooled fractions from density gradient tubes 3, 4, and 5 are shown in Table IV-
I. Other samples from the virus peak shown in Fig. IV-1 a provided similar 
results. The virus preparations labeled "purified" in these experiments were 
approximately 67-fold more pure than the crude virus preparation. 
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FIG. IV-1 . Density gradient purification of EMC-D virus. Open squares are 
density results of fractions without virus (centrifuge tube #6). Closed squares 
are virus titers obtained from fractions (a) pooled from centrifuge tubes #3-5; 
and (b) from centrifuge tube #2. 
TABLE IV-I. EMC-D VIRUS PURIFICATION. 
Total Virus Total Virus Protein Total Protein Purification 
Sample volume titer virus recovery cone. protein recovery indexa 
(ml) (pfu/ml) (pfu) (%of initial) (llg/ml) (llg) (% of initial) 
Crude pool 258 5.4x1 07 1.4x1010 100 1,790 4.6x105 100 
Freon supernate 323 8.4x1 07 2.7x1010 192.8 1,040 3.4x105 73.9 2.6 
Acid precipitate 5.5 2.7x107 1.5x1 os 1.1 332 .8 1.8x1 oJ 0.4 2.8 
Density gradientb 0.06 5.7x107 3.4x106 0.02 24 .8 1.4 0.0003 66.7 
a Purification index = percentage recovery of virus+ percentage recovery of protein. 
b Density gradient sample #25 from 3-5 pooled tubes was assayed. 
Ol 
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Diabetogenicity of crude and purified virus preparations. The number 
of male mice that developed diabetic signs by day 7 post virus inoculation 
(p.i. ) was directly proportional to the dosage of virus given whether the virus 
was the crude or the purified preparation (Table IV-11). Both parameters for 
diabetic signs (glycosuria and plasma glucose) were in agreement in samples 
from male mice on the day of sacrifice. Two of 5 female mice given 4 x 1 Q4 pfu 
of purified virus were diabetic by plasma glucose, but only one had glycosuria 
by Diasti x®. The females given the same dosage of crude virus failed to 
develop any signs of diabetes. All of the female mice which were tested 
developed neutralizing antibodies. Only the lowest dosage of virus failed to 
infect the male mice sufficiently to cause every mouse to produce antibodies. 
At this lowest virus dosage, only those male mice infected sufficiently to 
produce circulating antibodies became diabetic. 
Glycosuria , plasma glucose, and neutralizing antibody data gathered 
from mice sacrificed 9 or 21 days post virus inoculation are summarized in 
Table IV-III. Glycosuria data from day 7 are included for comparison with data 
from the first experiment. Standard deviations for the mean values of plasma 
glucose and neutralizing antibody concentrations are shown in Table A-1 of 
the Appendix . Neutralizing antibody data are not combined since the antibody 
titers would be expected to be, and were significantly higher in those mice 
sacrificed 21 days after infection than in those sacrificed 9 days p.i. 
A time-line with events of change, either cure from previous glycosuria 
or death, indicated on the days they were observed is depicted in Fig. IV-2. 
The type of virus pool and the concentration of virus used in the mice involved 
in each event is represented by the location and the type of symbol , 
respectively. 
Four mice out of 63 inoculated with crude virus died during the 
TABLE IV-11. TITRATION OF CRUDE vs PURIFIED EMC-D VIRUS POOLS. 
MICE WERE SACRIFICED 9 DAYS POST VIRUS INOCULATION. 
Titer of virus GI}'QQS!Jria (pQS.l!Qlal) Plasma gii.!QQS~ (da}' 9) 
inoculum Da}'7 D~9 Qrud~ P!.!rifi~Q 
(pfu/mouse) Crude Purified Crude Purified Pos.a/total Meanb Pos./total Mean 
4 X 103 717 9/10 8/10 9/10 9/10 518±165 9/10 541±180 
4 X 104 9/10 10/10 10/10 10/10 10/10 593±167 9/9 517±120 
4 X 105 10/10 9/9 10/10 9/10 10/10 567±95 9/10 498±167 
4 x 105 female 10/10 5/5 10/10 6/6 7/10 358±125 6/6 466±106 
a <!3 S.D. above the mean plasma glucose concentration of control mice. 
b mg/100 ml {±S.D.) 
c Units/0.1 ml of plasma. 
Neutral. antibodyc 
(m~an +S.D.) 
Crude Purified 
704±466 555±393 
597±283 443±309 
354±185 482±209 
458±248 627±508 
(J) 
w 
TABLE IV-III. TITRATION OF CRUDE vs PURIFIED EMC-0 VIRUS POOLS. 
MICE WERE SACRIFICED 9 OR 21 DAYS POST VIRUS INOCULATION. 
Titer of virus Data from ~!da(llQSllQ!aD 
Inoculum mice sacri- DiltZ Cl<ri9 Da~Zl 
(pfu/mouse) !iced on Crude Puri- Crude Puri- Crude 
(day) tied tied 
4 X 103 9 717 .. 911o·· 511o·· 911o·· 
21 0/5 2/3 •• 0/5 2/3 •• 0/5 
Combined 7/12 •• 11/13 •• 8/15 •• 11/13 •• 
4 X 104 9 911o·· 1011o·· 1011o·· 1011o·· 
21 2/3 •• 4/4 •• 1/3 4/4 •• 1/3 
Combined 11113 •• 14/14 •• 11/13 •• 14/14 •• 
4 X 105 9 10/1o·· 9/9 •• 1011o·· 911o·· 
21 4/4 •• 515·· 4/4 •• 2/4. 3/4 •• 
Combined 14/14 •• 14/14 •• 14/14 •• 11/14 •• 
4 x 105 female 9 1011o·· 515·· 1011o·· 6t6•• 
21 2/6. 0/5 1/4 0/5 017 
Combined 12/15 •• 511o·· 11/14 •• 6/11 •• 
0 9 0/19 0/19 
21 0/10 0/10 0/10 
Combined 0/29 0/29 
a ~3 S.D. above the mean plasma glucose concentration of control mice. 
b mg/100 mi. 
c Units/0.1 ml of plasma. 
d Sample not available from one mouse. 
• P<0.05; •• P<0.01; compared to controls. 
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Fig. IV-2. Time-line diagram of cures or deaths in mice inoculated with crude or purified preparations of EMC-D virus. 
•, 4 x 1 Q3 pfu; x, 4 x 1 Q4 pfu; o, 4 x 1 Q5 pfu; •, female; /\, mean day of change--all mice; !J., mean day of change--male 
mice only. 
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experiment. The mean day of death for these mice was 7.0 ± 2. 7. Although 
the cause of death was not determined, it did not seem to be due to central 
nervous system infection because the mice that died did not show obvious 
signs of paralysis. A general parenteral infection by the virus would seem 
more likely. Three of the mice were noted to have a bright red and swollen 
penis just before death. One of the mice had a bloody penis. In general , the 
mice suddenly appeared very ill , and died within 1 or 2 days. Of the 59 mice 
(42 males and 17 females) that lived to provide a blood sample , 3 failed to 
produce circulating antibody specific for the virus. All 3 of these mice were 
males that had been inoculated with 4 x 103 pfu of crude virus. One of these 
antibody-negative mice was sacrificed on day 9 and the other 2 on day 21 p.i. 
Five of the 65 mice inoculated with purified virus died prior to day 21 , 
with a mean day of death of 9.2 ± 3.1. All of the 59 mice that provided enough 
blood to test (1 diabetes-negative female sacrificed on day 21 provided 
insufficient blood for the antibody assay) had ~80 units of antibody /0 .1 ml of 
plasma. 
None of the mice that died during the experiment developed glycosuria 
which remitted before death. However, 2 of the male mice that died (days 8 
and 12) appeared to be progressing toward remission just prior to death, in 
that the concentration of glucose in their urine samples was decreasing. Both 
of these mice had received purified virus. Two other male mice that died (days 
9 and 13) were also positive for glycosuria at the time of their deaths. One of 
these mice had received 4 x 104 pfu of crude virus and the other had received 
4 x 105 pfu of purified virus. The 3 mice that died prior to day 8 had never 
developed glycosuria, and the 3 that died after day 8 were all glycosuric at the 
time of death. The 3 mice that died on day 8 included 2 without glycosuria and 
1 with glycosuria. 
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Five of the mice given crude virus spontaneously recovered from 
glycosuria before they were sacrificed. The mean day of cure for these mice 
was 1 0.8 ± 3.0. Four mice which were given purified EMC-D virus recovered 
with the mean day of cure being 9.2 ± 1.9. 
Discussion. The greatest purification ratio for the EMC-0 virus was 
obtained within the peak area of infectious virus in the density gradient 
centrifugation . The virus within that peak was approximately 67 times more 
pure than was the crude pool. 
Most of the data was statistically significant when infected mice were 
compared to uninfected control mice, as seen in the P values given in Tables 
IV-II and IV-III. When crude virus-infected mouse data was compared to data 
from mice infected with purified virus, there was no statistically significant data 
(P :-;; 0.05). The number of male mice which developed diabetic signs was not 
statistically different (P > 0.05) according to the purity of the virus. These 
differences also varied according to virus dosage and according to experiment 
performed, but not to an extent to make them statistically significant. Female 
mice were less sensitive to the diabetogenicity of the virus . Their lack of 
diabetic signs was not due to an ability to prevent a generalized infection by 
the virus, since each of the female mice tested for circulating antibodies had 
titers ~1 00 units/0.1 mi. When the virus inoculum was increased 1 0-fold, the 
percentage of female mice which developed diabetes was nearer to that of the 
male mice. In fact, in the case of higher virus inoculum, the only statistically 
significant difference (at P :-;; 0.05) between the number of males and females 
that developed diabetes was when purified virus was used and numbers of 
mice with glycosuria at 7 days p.i. were compared. 
The crude and purified virus preparations were almost equally 
infectious as judged by the number of mice that developed neutralizing 
68 
antibodies. It is interesting that all of the mice that failed to develop detectable 
circulating antibodies specific to the virus also did not develop diabetic signs; 
however, the development of circulating antibody alone was not sufficient to 
cause diabetic signs. Some of the mice with very high antibody titers, as high 
as 1920 units/0.1 ml, also had negative tests for glycosuria and their plasma 
glucose concentrations were very near, or even below, the mean 
concentration found in control mice. 
The extended time between infection and sacrifice did not increase the 
percentage of male mice which became diabetic, regardless of the virus pool 
used for infection. None of the mice became diabetic between day 9 and day 
21 p.i. Only one of the female mice apparently became glycosuric between 7 
and 9 days p.i., and that could have been an artifact due to a history of no 
urine samples prior to day 9. Some mice recovered from the diabetic state 
after day 7 p.i. The reasons for recovery of some mice when others remained 
strongly diabetic is not known. 
No significant differences in the numbers of mice reversing to normal 
from glycosuria could be seen when either crude or purified preparations of 
virus were used. Equal numbers of animals died or went into remission during 
the experiment. Most of the animals which reversed from glycosuria or died, 
did so within 9 days of introduction of the virus; however, some changes were 
seen as long as 15 days after virus inoculation (Fig. IV-2). 
The relative frequencies of male mice which died was somewhat dose 
dependent in that none given 4 x 103 pfu of virus died, but equal numbers 
died when given either 4 x 1 04 or 4 x 1 os pfu. Unexpectedly, the male mice 
given the highest dose of virus were also the ones that had the highest cure 
rate (14.8%). Those given 4 x 104 or 4 x 103 pfu of virus had lower cure rates 
(7.4% and 6. 7%, respectively). The differences in recovery rates were not 
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statistically significant. The mice were able to cure themselves in a way that is 
not understood. 
The death rate of mice given 4 x 1 as pfu of virus was slightly higher 
(4/35) when purified virus was used to infect than when crude virus was given 
(2/33) . The cure rate for mice given 4 x 1 as pfu of purified virus was also 
higher (3/3a) than when crude virus was given (2/31 ). These differences were 
not statistically significant. 
Conclusions. Additional mice were not found to become diabetic 
during the extended time between infection and sacrifice. In fact , just the 
opposite occurred. Some mice that had been diabetic by glycosuria early in 
the experiment spontaneously recovered and returned to normal during the 
extended time period. These mice evidently retained some functioning beta 
cells that were able to regenerate sufficiently to produce adequate levels of 
insulin. It is possible that even more cures would have occurred if many of the 
glycosuric mice had not been sacrificed on day 9 p.i. There was no significant 
difference in remissions from diabetes when the use of crude virus was 
compared to that of purified virus. 
No extraneous (non-infectious viral or cellular) material was shown to 
contribute to, or oppose, the diabetogenic capabilities of EMC-D virus. There 
were no statistically significant differences in the numbers of mice that died, 
showed remission from glycosuria, developed diabetes, or developed 
antibody to the virus when either crude or purified virus was used for infection. 
Titration of each type of virus pool (crude or purified) yielded approximately 
equal numbers of mice in each of the categories above, when equal 
concentrations of virus were used from each type of pool. Thus, it seems that 
the infectious EMC-D virus particle is intrinsically diabetogenic. However, 
purification of the virus sufficient to remove all of the cell material from the 
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preparation would be necessary to absolutely prove that cellular material does 
not play a part in the diabetogenicity of EMC-D virus. 
CHAPTERV 
HOST DEFENSE ACTIVITIES IN 
RELATIONSHIP TO DIABETES 
INDUCED BY EMC-D VIRUS 
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Introduction. Previous investigators have demonstrated a variety of 
different characteristics that affect the outcome of EMC virus infection of mice, 
especially relating to whether or not diabetes is induced in the animal. It is 
impossible to determine the characteristics that are necessary for the infection 
to lead to diabetes because of the many conflicting results obtained by these 
investigators. However, host defense mechanisms appear to be one group of 
characteristics that is consistently important in the outcome of this infection. 
This study was designed to obtain additional information regarding what is 
occurring to selected host defense mechanisms at the time virus infection is 
inducing the diabetic state in mice. 
Many strains of mice have been shown to be resistant to the 
diabetogenicity of EMC virus. Boucher et al. (66) recognized a genetic trait of 
resistance and Yoon and Notkins (67) attributed the inherited trait to a 
resistance of the beta cells of the pancreas to infection by EMC virus. 
However, experiments by Dafoe et al. (72) demonstrated that host factors 
other than inherited pancreatic resistant factors are most important in 
determining susceptibility to the diabetogenicity of EMC virus. 
Testosterone has been shown to be very important in causing mice to 
become susceptible to the diabetogenicity of EMC virus, at least in certain 
strains of mice (73). Giron and Patterson (74) found that females of one strain 
of mouse (DBA/2J) remained resistant to EMC-D-induced diabetes when 
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treated with testosterone even though ICR Swiss female mice became 
susceptible when treated with testosterone. 
Giron et al. (75) also found that ICR Swiss mice must be older than 7 
weeks for EMC·D virus to induce diabetes. In mice younger than 7 weeks, the 
virus induced a lethal encephalitis instead of diabetes. 
Yoon et al. (15) speculated that differences in IFN-stimulating ability of 
their 8 and D variants of EMC virus could account for the differences in 
diabetogenicity exhibited by the two variants. They found that the D variant, 
which caused near 100% of the mice injected to develop diabetes, stimulated 
little, or no, IFN production in either cell culture or mice. The 8 variant, with 
near 0% diabetogenicity, had the opposite IFN·stimulatory ability , with normal 
levels being stimulated in both cell culture and mice. 
IFN or its inducers have different effects on the diabetogenicity of EMC· 
D virus , according to results reported by others (17, 18). While IFN· B, or a 
variety of IFN inducers, blocked the diabetogenic effect of the virus in SWRJJ 
mice, no effect was seen in ICR Swiss mice when the same treatments were 
used according to a report by Giron's group (17) . The same group (18) 
extended the studies and reported that if IFN·B or IFN·Y were given at a 
specific time in the infection, it exacerbated the diabetogenic nature of the 
virus. 
Earlier investigators (19, 20, 76) reported that the cellular immune 
system must be functional for EMC strain M virus to cause diabetes. They also 
found that diabetes is caused even in the absence of a funct ional humoral 
immune system. 
Each of these prior findings emphasizes that the diabetogenicity of 
EMC virus is certainly affected by the resistance mechanisms of the mouse. 
Exactly how these mechanisms influence the course of development of the 
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diabetic syndrome has not been elucidated. The research reported here was 
undertaken with the goal of discovering what happens to some of the 
resistance mechanisms of the mouse during induction of the diabetic state by 
EMC-D virus infection. 
Materials and Methods. Mice. Male SJUJ mice were used in these 
experiments. They were obtained and maintained as outlined in Chapter Ill. 
Medium, cells, and virus. All were explained in Chapter Ill. 
Titration of animal serum for neutralizing antibody. These titrations 
were done in a manner similar to that outlined for mouse plasma samples in 
Chapter Ill. 
Titration of interferon. Samples were titered in a manner similar to that 
outlined in Chapter Ill for the titration of poly I:C-induced IFN with the following 
exceptions: 1) Only L-cells were used for the titrations. 2) Three wells, instead 
of four, were used for each dilution. and 3) The plates were incubated for only 
22 hr at 37°C before the samples were aspirated from the cells and 0.1 ml of 
virus (VSV only) was placed in each well. 
Plaque assay of density gradient samples. Plaque assays to determine 
the concentrations of EMC-D virus present in density gradient samples were 
carried out as described in the materials and methods section of Chapter Ill. 
Comparison of diabetic signs with signs of EMC infection at various 
intervals. Male SJUJ mice were inoculated by the i.n. route with the L-cell-
passaged virus at a concentration of 4 x 1 as pfu/mouse or with an equal 
volume (20 J.!l) of sterile virus diluent for control mice. At various intervals from 
0 to 125 hr after virus exposure, mice were sacrificed by bleeding and tissue 
samples were taken; some samples were frozen and some were fixed in 
buffered 10% formalin, for future analysis. Analyses were made of the urine 
samples taken at the time of sacrifice by use of Clinistix®; Diastix® were used 
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after the Clinistix® tests were positive. Two mice exposed to virus and one 
control mouse were sacrificed at each interval. 
Titration of infectious virus from mouse tissues. Tissues stored at -80° 
were weighed, thawed and homogenized in sufficient test medium to prepare 
a 10% (w/v) suspension . In some cases, especially with lung and thymus 
tissues, only a 5% suspension was made because there would have been 
insufficient volume for the homogenizer to function if a 10% suspension had 
been made. 
The tissue homogenates and plasma samples were diluted in test 
medium by serial 1 0-fold dilutions. One-tenth ml of each dilution was placed 
in each of triplicate wells of a 96-well plate containing monolayers of L-cells. 
The plates were wrapped with Saran Wrapn.c (The Dow Chemical Co., 
Indianapolis, IN), incubated at 37° C for 3 days, and the CPE was read by use 
of an inverted microscope. Virus titers were calculated by the 50% endpoint 
method of Reed and Muench (94) and expressed as cell culture infectious 
dose, 50% endpoint (CCIDso)/0.1 mi. 
Guinea pig serum collection. Guinea pigs were bled by cardiac 
puncture after they had been anesthetized by intramuscular (im) injections of 
VETALAR® (Ketamine HCI Injection, NF) Veterinary--equivalent to 100 mg/ml 
Ketamine (Parke Davis and Co., Detroit, Ml) plus Acepromazine (1 :1 0). 
Collected blood samples were placed in 15 ml sterile Corning centrifuge tubes 
(Corning Glass Works, Corning, NY) and allowed to clot. Each clot was 
rimmed with a wood applicator stick and the tube was centrifuged to separate 
the serum, which was collected and frozen for future assay. 
Preparation of primary antibody specific for EMC-0 virus. Virus was 
purified by CsCI density gradient as outlined in Chapter IV with the following 
changes: 1) Four and one-half ml of CsCI was used in each of 4 tubes. 2) 
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Four and one-half ml of sterile PBS was added to 2 of the tubes and 4.5 ml of 
the virus to each of the other 2 tubes (tubes 1 & 4 of the ultracentrifuge). 3) 
The tubes were centrifuged at 35,000 rpm for 38.5 hr. 4) Both virus-containing 
tubes had a visible, ragged-looking heavy band approximately half way down 
in the gradients of each tube. This precipitate, which looked as though it were 
protein , was collected mainly in fractions numbered 9 & 10. However, the 
precipitate was seen to form a very narrow "stream" down the center of each 
tube as fractions were beginning to be collected. The visible "stream" reached 
the bottom of the tube at approximately the time that fractions 4 and 5 were 
being collected. 
As the fractions were being collected from tube #1 and the precipitate 
reached the collection needle, it plugged the needle until sufficient pressure 
was applied to suddenly break the plug loose. The drops flowed so rapidly 
from the tube that two fractions (20 drops) were collected in fraction tube #9. 
The very rapid flow caused some visible mixing action at the very bottom of the 
density gradient tube. 
The fractions obtained from the density gradient tubes were titered by 
plaque assay to determine which samples contained the highest 
concentrations of infectious virus. The samples with peak virus titers (#1-8, 
#1-9, #4-8, and #4-9) were selected for dialysis. The first number represents 
the density gradient centrifuge tube number from which fractions were 
collected. The second number represents the fraction number collected from 
that centrifuge tube, i.e. #1-8 is fraction number 8 collected from centrifuge 
tube number 1. These samples were diluted 1 :10 in sterile 5 mM phosphate 
buffered saline, pH 7.3 (PBS-1) and dialyzed against PBS-1. All dialyses 
occurred at 4°C with stirring. The first dialysis was for 2 hr in 500 ml of PBS-1, 
the second for 4 hr in 500 ml of fresh PBS-1, and the final dialysis was for 19 
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hr in 1,000 ml of fresh PBS-1. The samples were removed from the dialysis 
tubing and placed in freezer vials for storage at -80°C. All samples were clear 
except #1-9 , which had a white precipitate. 
Portions of sample #4-9 were diluted 1:3 in sterile PBS-1 and in 10% 
buffered formalin. The sample diluted in PBS-1 was placed at 49°C for 15 hr 
for heat inactivation (4-9-11) and the sample in formalin (4-9-formalin) was 
placed at 4°C for an equal time period to allow inactivation by formalin action. 
Sample #1-9 was diluted 1 :16 in sterile PBS-1 and placed at 49°C for 15 hr for 
heat inactivation (1-9-11) . Samples of 1-9-11, 4-9-11, and 4-9-formalin were 
placed on L-cells to determine if complete inactivation had occurred. Neither 
of the heated samples was completely inactivated, so they were additionally 
heated at 55°C for 20 hr, which completely inactivated the virus infectivity in L-
cells. The formalin-treated sample was completely inactive in L-cells. 
Three female Hartley guinea pigs were used. One of the guinea pigs 
received 0.3 ml of an equal volume mixture of 1-9-formalin and Freund's 
complete adjuvant (FCA) (Calbiochem-Behring Corp., LaJolla, CA) in each 
rear flank by the im route. The mixture was made by forcefully injecting the 
FCA into the virus preparation, which was already in a serum vial. The mixture 
was pulled into the syringe and forcefully injected back into the vial 2 times. 
The resulting milky-white suspension was used for injection. The two heat-
inactivated virus samples were mixed in equal volumes with FCA, as outlined 
above. These suspensions were injected im into each of the other two guinea 
pigs. The next day, one of the latter 2 guinea pigs was found dead and 2 days 
later, the second guinea pig that had received heat-inactivated virus died. 
Two male Hartley guinea pigs were bled. One was injected im with a 
sample of heat-inactivated virus, without adjuvant, while the other received a 
formalin-inactivated virus sample im without adjuvant. The guinea pigs were 
77 
bled and given booster shots on somewhat different schedules, as shown in 
Table V-1. 
Sample #1·9 from the density gradient centrifugation was emulsified 
with an equal volume of FCA by repeatedly (approximately 20 total syringe 
pushes) forcing the mixture between 2 syringes (5 ml) connected by 16 gauge 
x 1.5" needles and silicone tubing. When a drop of the emulsion on water 
held a bead, it was considered sufficiently emulsified (1 06). This emulsion 
was immediately injected into the gluteal muscles of a New Zealand White 
male rabbit. Approximately 2.6 ml of the emulsion was divided into 4 injection 
sites, 2 on each side of the rabbit. The virus was not inactivated in any 
deliberate manner prior to injection. The rabbit was bled and boosted with 
virus injections as summarized in Table V-11. 
Serum collection from rabbit. The outside of the chosen ear was 
clipped closely by use of electric clippers. Xylene was rubbed on the central 
ear artery and the artery was vigorously rubbed from the base of the ear 
toward the tip with a dry cotton ball. A sterile 20 gauge x 1" injection needle 
was inserted into the upper end of the artery with the needle pointed toward 
the head of the rabbit. Blood was allowed to flow from the needle hub into a 
sterile Venoject® AutoSep,.,. tube with inert separator gel and clot activator 
(Terumo Medical Corp., Elkton, MD). Immediately after the blood was 
collected, a sterile cotton swab was pressed tightly over the hole left when the 
needle was withdrawn, and held until a clot stopped the bleeding. The ear 
was then thoroughly washed with warm water and baby shampoo. After 
thoroughly rinsing and drying the ear, Sulfa Urea Ointment (Veterinary 
Laboratories, Inc., Lenexa, KS) was applied and rubbed into the skin of the 
ear. Alternate ears were used with each successive bleeding when this was 
possible. The blood was allowed to clot at room temperature and then 
TABLE V-I. GUINEA PIG INJECTION AND BLEEDING SCHEDULES 
AND ANTIBODY TITERS. 
Pig no. Action Number of days from initial antigen inoculation 
Bleed 0 
lnjecta Ob dead on day 4 
2 Bleed 0 
Inject oc dead on day 1 
3 Bleed -1 26 34 60 117 158 188d 
Tit ere 0 1.0 1.0 1.0 3.4 4.2 
Inject ot 269 519 111 h 152h 18Qi 
4 Bleed -1 33 42 71 
Titer 0 1.3 
Inject Qk 34k sam 79m dead on day 83 
5 Bleed -8 13 34 78 92 163d 
Titer 0 0 0 0 0 
Inject on 26n nm 86P 
a All injections by im route unless otherwise stated in footnote. 
b 4-9-6 + Freund's Complete Adjuvant. 
c 1-9-6 + Freund's Complete Adjuvant. 
d Sacrificed 
e Log1o neutralizing antibody titer (0 indicates no antibody detected) . 
t 4-9-formalin + Freund's Complete Adjuvant. 
9 4-9-formalin no adjuvant. 
h 4-9, live virus, no adjuvant. 
i 4-8, live virus, no adjuvant. 
k 4-9-6, no adjuvant. 
m EMC-D, crude pool, 1 Q5.9 pfu given by i.n. route. 
n 1-9-formalin, no adjuvant. 
P Both EMC-0, crude pool by i.n. route and 1-9-formalin, no adjuvant. 
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TABLE V-11. RABBIT INJECTION AND BLEEDING SCHEDULES AND NEUTRALIZING ANTIBODY TITER. 
Action Number of days from initial antigen inoculation 
Bleed -4 3 10 17 24 31 38 59 63 416 418 420 422 427 431 437 452 456 466 
Titera n.d.b 1.53 4.31 3.63 3.54 3.91 3.86 3.85 3.57 3.00 3.08 
Inject oc 21d 31e 
a Neutralizing antibody titer (log1o units/0.1 ml) . 
b None detected. 
59' 4169 
4.15 4.30 4.30 4.15 4.1 5 4.30 4.15 
452h 
c 1-9 (live), (0.5 ml + 1.0 ml PBS, emulsified with 1.5 ml Freund's complete adjuvant), 2.6 ml by im injection. 
d 4-9 (live), 0.5 ml undilute by iv injection. 
e 4-9 (live), 0.25 ml undilute by iv injection. 
t 1-9 (live), 0.1 ml undilute by sc injection. 
g EMC-0, Pur. #1, 9-27-85 (live), 1.0 ml of a 1:10 dilution by iv injection. 
h EMC-0, Pur. #1, 9-27-85 (live), 1.0 ml of a 1:10 dilution by iv injection. 
-...J 
<0 
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centrifuged at the highest speed setting of an International clinical centrifuge 
(International Equipment Co., Needham Heights, MA) for 5 minutes. The 
serum was collected from the top of the plug and dispensed to freezer vials 
which were placed at -80°C or stored at refrigerator temperature for later 
assay of antibody in the serum. 
Separation of lgG from lgM and other serum components. ZetaChrom"' 
60 D1 Amine Disks (AMF Laboratory Products, 400 Research Parkway, 
Meriden, CT) were utilized as outlined in the product use brochure supplied 
with the disks. In brief, the process was as follows. The sample of serum was 
diluted 1:10 in "Buffer A" (0 .015M NaH2P04 , pH 6.3, conductivity 1.0 milli 
mho/em). The ZetaChrom 60 disk was equilibrated by washing it with 75 ml of 
"Buffer B" (0 .1 M NaH2P04 , pH 6.8, conductivity 9.0 milli mho/em) and then 
passing 75 ml of Buffer A through the disk. The sample was applied to the 
disk by use of a syringe with the flow rate adjusted to 5-10 ml/min. The effluent 
from the disk was collected as purified lgG. The disk was washed with an 
additional 28 ml of Buffer A to remove all of the lgG. Bound proteins, including 
lgM, were eluted by passing 50 ml of Buffer B rapidly through the disk. From 
the time the sample was applied until the entire 50 ml of Buffer B was pushed 
though the disk, 4.0 ml fractions were collected as disk effluent. The O.D. (at 
280 nm) of each fraction was read on a Perkin-Elmer, Coleman 124 double 
beam spectrophotometer (Hitachi Ltd., Tokyo, Japan). using 1 em cuvettes. 
Each sample was titered for neutralizing antibody. 
Other primary antibody preparations. Anti-porcine insulin prepared in 
the guinea pig was obtained from Miles Scientific Division, Miles Laboratories, 
Inc., Naperville, IL. Rabbit anti-mouse IFN (alpha) antiserum was purchased 
from Chemicon International, Inc., Los Angeles, CA. Anti-mouse IFN (beta) 
globulin raised in a rabbit was purchased from Lee BioMolecular Research 
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Laboratories, Inc., San Diego, CA. Rabbit anti -mouse IFN (gamma) was 
obtained from Enzo Biochem, Inc., New York, NY. 
Immunohistochemical staining. Tissue sections, 7 ~m th ick, were 
prepared by the Animal , Dairy, and Veterinary Science diagnostic group, 
using mouse tissues that had been placed in 10% buffered formalin solution 
after they were freshly excised from the mice. The tissues were stored in this 
solution until they were embedded and sectioned. The sections were placed 
on glass slides without gelatin or other added material to fi x the section to the 
slide. It is important that certain adherence factors, especially gelatin, be 
avoided since these can cause a strong false positive background staining 
(Vectastain® Product Insert) . 
The Vectastain® ABC immunoperoxidase staining procedure 
(Vectastain ABC Kits, Vector Laboratories, Burlingame, CA) was generally 
followed but some major adjustments were made to avoid the non-specific 
staining initially experienced. The following procedure was found to be 
satisfactory. The sections were deparafinized by soaking in 3 separate baths 
of Histosol (National Diagnostics, Somerville, NJ) for 2 minutes in each. 
Hydration of the tissues was accomplished by 2 separate baths of absolute 
ethanol (EtOH) for 30 seconds each, then 2 baths of 95% EtOH (30 seconds in 
the first and 10 dips in the second), 10 dips in a 50% EtOH bath , 10 dips in a 
tap water bath and 5 minutes in a distilled water bath. Blocking serum (1 .8% 
normal serum from a species of animal in which the secondary antibody was 
made) was flooded over the tissue sections and the slides were placed in a 
humidified chamber to incubate for 20 minutes at room temperature (all steps 
took place at room temperature). Excess serum was blotted from the slides 
and primary antibody used to flood the tissue. The slides were again placed 
in the chamber for 30 minutes. The sections were rinsed for 10 minutes in 
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1 OmM phosphate-buffered saline, pH 7.6 (PBS-2) and the slides were 
incubated for 30 minutes with diluted biotinylated antibody solution. The 
sl ides were again rinsed for 10 minutes in fresh PBS-2 and incubated for 30 
minutes with Vectastain® ABC reagent. The slides were rinsed for 10 minutes 
in fresh PBS-2 and exposed for 10 minutes to the peroxidase substrate 
solution (320 ml of 50mM Tris buffer, pH 7.6 ; 9.3 g NaCI ; 160 mg 3,3'-
diaminobenzidine tetrahydrochloride [DAB]; 1.6 ml 8% NiCI2 ; all filtered 
through Whatman #2 paper, then immediately before use 43 Ill of 30% H20 2 
was added, with mixing). The slides were rinsed in tap water for 5 minutes 
and placed in methyl green/pyronin counterstain for 1.5 minutes. The tissues 
were rinsed and dehydrated before cover slips were mounted. Rinsing and 
dehydration steps were accomplished by ten dips in each of distilled water, 
acetone (2 baths) , acetone/Histosol (50:50) , and Histosol. The slides were 
placed in a fresh Histosol bath until cover slips were mounted with Permount 
(Fisher Scientific, Pittsburgh , PA) . 
Histogen® immunohistology kits (BioGenex Laboratories, Dublin, CA) 
were used for some of the staining. In this procedure, the tissue sections were 
deparafinized by soaking in 2 separate baths of Histosol for 3 minutes each. 
The tissues were hydrated by 2 separate baths of absolute EtOH, 3 minutes 
each, followed by 2 baths of 95% EtOH, 3 minutes each, and finally 5 minutes 
in 10 mM potassium phosphate buffered saline, pH 7.6 (PBS-3) . Blocking 
serum was placed on the tissues for 20 minutes at room temperature (all 
incubations took place at room temperature) . Excess serum was removed and 
primary antibody was placed on the slides for 30 minutes. The slides were 
rinsed well in PBS-3 and link antibody (streptavidin-labeled antibody specific 
to the lgG of the species in which the primary antibody was raised) was 
allowed to react for 20 minutes. The slides were rinsed again in PBS-3 and 
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labeling reagent (biotinylated peroxidase) was flooded over the slides for 20 
minutes. The slides were rinsed well with PBS-3 and freshly prepared 
substrate solution was placed on the slides for 5-40 minutes. The slides were 
rinsed with glass distilled water, counterstained with hematoxylin, and cover 
slips were mounted with aqueous mounting medium. 
Results. Diabetic signs compared to virus yield and resistance 
parameters at various time periods. Mice infected i.n. with EMC-D virus were 
killed at varying times post inoculation (p.i.) and various disease signs were 
assayed. Three parameters of infection and resistance , virus yield, IFN 
induction, and neutralizing antibody production, are depicted graphically in 
Fig . V-1 as they developed at various times in the plasma of infected mice. 
Infectious virus was not detectable (< 1 oo.7 CCID50/0.1 ml) in the plasma until 
11 hr p.i., but achieved a peak titer of 1 os.4 CCID50/0.1 ml at 54 hr, and 
declined to non-detectable levels by 125 hr p.i. The plasma IFN activity was 
undetectable until 29 hr, then reached a maximal level by 35 hr, declined 
slightly in titer between 35 and 96 hr, and dropped to undetectable levels at 
125 hr p.i. Neutralizing antibody began to show detectable levels in the 
plasma as early as 72 hr after virus inoculation and continued to increase in 
titer through the end of the experiment, 125 hr p.i. 
Diabetic signs are represented by plasma glucose levels in Fig . V-2. 
The concentrations rose sharply from the normal level (below 200 mg/1 00 ml) 
to well above normal between 96 and 125 hr following i.n. introduction of the 
virus. Glycosuria was seen in one of the virus-infected mice at 96 hr p.i. This 
mouse was not sacrificed to obtain plasma glucose measurements until 125 hr 
p.i. 
Results of virus, IFN, glucose, and neutralizing antibody in blood 
plasma are combined from 2 experiments. One of the experiments had 
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FIG. V-1. Comparison of virus, IFN, and neutralizing antibody concentra-
!ions in the plasma of mice at various times after inoculation of EMC-D virus by 
the i.n . route. Male SJUJ mice were inoculated with virus and two mice were 
sacrificed at each of various time periods to collect plasma for later assay for 
virus (CCIDS0/0.1 ml), 0 ; IFN (units/0.1 ml) , • ; and neutralizing antibody 
(units/0.1 ml), ~ . Single control mice (receiving virus diluent only) sacrificed 
at each time period were uniformly negative for tested items in the plasma. 
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FIG. V-2. Plasma glucose concentration in mice at various times after i.n. 
inoculation with EMC-D virus or with sterile virus diluent. Individual mice in-
oculated with virus, II and II ; individual mice inoculated with virus diluent II . 
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sample times ranging from 0 to 71 hr post-virus inoculation and solid tissues 
were taken for analysis of virus as well as for immunohistochemical staining. 
The other experiment had sample times ranging from 0 to 125 hr post-virus 
inoculation and solid tissues were taken only for immunohistochemical 
staining. 
Although the virus concentration in the plasma of the mice was 
reduced somewhat by 71 hr p.i., the concentration in other tissues seemed 
generally to be increasing at this time, as seen in Fig. V-3. Only the thymus 
tissue, in addition to the plasma, seemed to have reached a peak of virus 
concentration prior to 71 hr p.i. 
Primary antibody specific for EMC-0 virus. Results of virus titrations of 
density gradient samples of the virus preparation partially purified for antibody 
stimulation are shown in Fig. V-4. The peak virus titer occurred in the sample 
with a density of approximately 1.36. Neutralizing antibody titers in the sera 
collected from the guinea pigs are shown in Table V-1. One of the guinea pigs 
developed a peak antibody titer of 1 o4.2 units/0.1 ml of serum. Table V-II gives 
neutralizing antibody titers of serum samples obtained from the rabbit. The 
highest titer reached was 1 Q4.31 units/0.1 ml of serum. Results of lgG 
separation from other serum components and titrations of neutralizing 
antibody in the serum samples of the rabbit are shown in Fig . V-5. The highest 
titer of neutralizing antibody was found in the lgG peak. However, the 
neutralizing antibody found in the lgM peak was approximately half as 
concentrated as that seen in the lgG peak fraction . 
Immunohistochemical staining with anti-insulin primary antibody. Islet 
cells stained very prominently in pancreas tissue of control animals and of 
virus-infected mice until 54 hours post-inoculation. At this time and after, the 
stain ing became spotty, Fig. V-6, or disappeared altogether in tissue sections 
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FIG. V-3 . EMC-D virus yields from tissue samples taken at various times 
after mice were inoculated by the i.n. route. Male SJUJ mice were inoculated 
with virus and sacrificed at various times after virus was given. The tissues 
were frozen until they could be homogenized as a 10% (w/v) suspension and 
the homogenate titered for infectious virus in cell culture. Symbols represent 
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titers obtained from the following tissues: •· plasma; Ill, pancreas; 1111 , spleen; 
r;a , kidney; [j, liver; m:l. lung; f:J, heart; and IE, thymus. 
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FIG. V-4. Virus titers of density gradient samples. Open squares are mean 
densities of samples from 2 density gradient control tubes. Closed diamonds 
are geometric mean virus titers of samples from 2 density gradient tubes with 
virus. Error bars represent the standard deviations of the sample means. 
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FIG . V-6 . Immunohistochemical staining of insulin (dark brown) in 
pancreatic tissue. (A) Section from an infected mouse at 54 hr p.i. Stained 
with Vectastain® ABC kit , guinea pig anti -porcine insulin used as primary 
antiserum. (B) Section from a control mouse; stained as above except that 
primary antiserum was omitted, as a negative control. 
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from virus infected animals. Sections of pancreas from control animals had 
islets that stained strongly throughout the 125 hr of the experiment. Pancreas 
tissue of mice infected with EMC-D virus and sacrificed 125 hr p.i. either 
completely lacked recognizable islets or the few islets present were devoid of 
stain. 
Immunohistochemical staining with anti-EMC-0 virus primary antibody. 
No specific staining of any tissues could be demonstrated with the guinea pig 
antiserum used as primary antibody, nor could any be demonstrated when the 
rabbit antiserum was used. However, when rabbit lgG isolated from the anti-
EMC-D virus antiserum was used as primary antiserum, specific staining of 
spleen tissue could be seen which began at 11 hr and showed staining 
through 71 hr p.i. No other tissue was specifically stained when the rabbit lgG 
was used as primary antibody. Uninfected control mice had no staining of any 
tissue. 
Staining with antibody specific for the three different types of mouse 
IFN. Immunohistochemical staining for IFN - ~ in the tissue sections seemed 
specific since sections treated with negative control serum instead of primary 
antiserum completely lacked stain in all tissues. However, when glandular 
tissue (pancreatic acini or tubular glands of the small intestine) was exposed 
to the primary antibody and stained, some nuclei were seemingly non-
specifically stained. Even control mice had tissues which stained well. The 
virus infected mice appeared to have darker staining tissues than tissues from 
control mice. The antiserum had a fairly low titer so that only 1 :20 or 1 :40 
dilutions could be used. 
Tissues exposed to negative control serum also did not stain when 
staining was done for IFN-a in the tissue sections. The only cells that stained 
in lung tissue when anti-IFN-a was used as primary antibody were smooth 
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muscle cells surrounding some of the larger airways. Tissues from uninfected 
control mice as well as virus infected mice had areas of plasma which stained 
quite well. The anti-IFN-a serum caused positive staining when diluted as 
much as 1 :100 or 1 :500. If diluted 1 :1,000 or more the endpoint was 
surpassed. 
Staining patterns for IFN-y was surprising in that thymus and spleen 
tissues from control mice stained a little more intensely than the same types of 
tissue from virus infected mice. Other tissues had uniform intensity of staining 
between tissues of control or virus infected mice. The staining seen in kidney 
tissue is represented in Fig. V-7. The anti-IFN-y antiserum could be diluted 
1 :1,000 or 1 :5,000 to obtain intense staining. 
Discussion. Experiments to determine the time of appearance of 
diabetic signs in mice relative to the signs of EMC virus infection showed that 
plasma glucose was not elevated until after infectious virus in the plasma was 
eliminated and neutralizing antibody was rapidly increasing in concentration . 
In this i.n. infection with a dose of virus designed to cause 100% of the mice to 
develop diabetes, the circulating IFN response pattern was very similar to that 
described by Yoon et al. (15). Their data indicated that the IFN titer peaks later 
and is sustained over a longer period than that seen in mice infected with the 
non-diabetogenic EMC-B virus. 
Of the 8 tissue types examined (blood, pancreas, spleen , kidney, liver, 
lung, heart, and thymus) , only blood and thymus reached peak virus titers in 
the 71 hr period studied. Titers in the thymus peaked at 47 hr and blood titers 
peaked at 59 hr. Since the virus was introduced by the i.n. route, it was 
surprising that virus appeared in pancreas, liver, blood, and thymus tissues 
before it was detected in lung tissue. Virus was not measurable in lung tissue 
until 23 hr p.i., whereas virus was detected in pancreas and liver as early as 4 
A 
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FIG. V-7. Immunohistochemical staining of mouse IFN-r in kidney tissue. 
(A) Section from a control mouse with specific staining (red) associated with 
the glomerulus. Stained with Histogen® kit, rabbit anti-mouse IFN-r used as 
primary antiserum. (B) Serial section from same mouse ; stained as above 
except that primary antiserum was omitted, as a negative control. 
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hr p.i. and in blood and thymus at 11 hr p.i. Spleen and kidney tissue had 
detectable virus as early as lung tissue. Heart tissue was the last tissue type 
(at 35 hr p.i.) to begin yielding detectable virus. This was also a surprise since 
the virus had initially been cultivated repeatedly in mouse heart tissue to 
obtain the M-strain of EMC virus. These results indicate that free virus 
transport in circulating plasma is abating well before diabetic signs begin to 
appear. 
Only one of the mice had glucose in the urine by 96 hr p.i., and that 
mouse was spilling even more glucose the next day when it was sacrificed 
(1 000 mg/1 00 ml at 96 hr and ~2000 mg/1 00 ml at 125 hr). It is possible that 
some immunological mechanisms are playing a role in the development of 
diabetes in the mice, since the signs of diabetes appear at the time antibody 
production is building strongly and after the virus has been largely removed 
from the circulation. Additional studies must be done to determine what is 
taking place to cause the diabetic signs to appear at this time. 
The staining for insulin in the tissues worked very well and seemed to 
be specific. However, it did not appear sensitive enough to stain insulin in the 
plasma that was contained in the tissue sections. It is possible that fixation 
with formalin masked the insulin antigens in the plasma but left sufficient 
insulin antigens unmasked in j3-cells to enable good staining to take place in 
the cells. 
At the time this investigation began, it was not possible to purchase 
antiserum directed against EMC virus. Since it was necessary to have a good 
primary antibody specific for EMC virus in order to discern those tissues 
producing virus antigen during the infection, production of antiserum in 
animals other than mice was necessary. Guinea pigs were the first choice, 
since Tyrrell (1 07) stated that they produced better antibody to rhinoviruses 
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(which are in the same family, picornavirus, as EMC virus) in general than did 
rabbits . It was thus reasoned that less antigen would be needed to illicit a 
good antibody response if guinea pigs were used. However, the results of 
attempts to produce antiserum that would cause specific staining in the 
immunohistochemical staining procedure were disappointing. Two of the 
inoculated guinea pigs died of unknown reasons and a postmortem 
examination (gross necropsy observations and histopathology) did not reveal 
the cause of death. Both animals appeared healthy the day before they were 
found dead in their cages. Other guinea pigs inoculated with virus produced 
neutralizing antibody in moderately high titers, but no specific staining could 
be obtained on the tissue sections. 
It is possible that lgM antibody was responsible for much of the 
neutralization of the virus. Any virus-specific lgM antibody would probably 
interfere with the immunohistochemical staining because the secondary 
antibody used was specific for guinea pig lgG. Thus, if lgM antibody covered 
some, or all, of the viral antigens in the tissues. there would be fewer sites at 
which lgG antibody could attach . The secondary antibody necessary for 
specific staining would then have few, if any, sites for attachment. 
Results of attempts to produce anti-EMC virus antiserum in the rabbit 
were more promising in that higher neutralizing antibody titers were obtained 
in this species. However, when these antiserum samples were used as the 
primary antibody in the immunohistochemical staining technique , a similar 
lack of specific staining was seen. It was decided to separate the lgG from the 
lgM of the rabbit serum, since it was easier to obtain large volumes of the 
rabbit serum and since this serum also had higher titers of neutralizing 
antibody than did the guinea pig serum samples. Once the lgG was 
separated, it was found to react specifically in the immunohistochemical 
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staining technique. The lgM must have been reacting with the virus antigens 
in the tissues to such an extent that lgG was not able to bind to these antigens. 
The secondary antibody was thus unable to attach and begin the network 
necessary to provide a visible marker at the site of virus antigen production. 
It was an unexpected finding that spleen tissue was the only tissue 
which stained in a specific manner when anti-EMC-0 virus antiserum was 
used. Infectious virus was isolated at respectable titers from all of the other 
tissues studied. In fact, infectious virus was recovered from pancreatic tissue 
at higher titers (on a per gram of tissue basis) than found in spleen tissue, 
except at 23 and 35 hr p.i. (Fig . V-3). Yoon et al. (15) had shown the presence 
of viral antigen in the islets of Langerhans of infected mice by direct 
fluorescence assay. They used mouse anti-EMC virus antibody labeled with 
fluorescein isothiocyanate (FITC) and frozen sections of mouse pancreas. No 
one has described staining sections other than pancreas tissue, and that 
tissue has only been stained by FITC-Iabeled anti-EMC virus antisera. 
The reasons for failure to specifically stain the EMC-0 virus antigen in 
all tissues are not known. However, it is known that fixation of the tissue can 
mask the antigens within the tissue. The antigens masked by formalin-fixation 
can often be partially rejuvenated by brief protease treatment (1 08, 1 09). 
Treatment of tissue sections with trypsin did seem to restore specific 
staining to lung, liver, kidney, heart, and thymus tissues. However, pancreas 
tissue was always dislodged from the slide during the trypsin treatments. 
Lung, liver and heart tissues were dislodged 2 of 5, 2 of 5, and 3 of 5 times , 
respectively, when trypsin treatment was tried on these tissues. Therefore, 
trypsin treatment is not recommended when one is attempting to stain several 
different tissues at several time periods in order to obtain comparative results. 
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Immunohistochemical staining for IFN-13 in the tissue sections seemed 
to be specific according to a lack of stain when negative control serum was 
used instead of primary antiserum , and according to the direct relationship 
between concentration of primary antiserum used and the resulting stain 
intensity. However, the staining of the nuclei of certain cells indicated that 
some non-specific staining was occurring, since IFN should be produced in 
the cytoplasm of the cell . This stain in the nucleus was possibly due to avidin 
binding to the nucleus, as had been seen on a much more pronounced scale 
when particular batches of distilled water were used to prepare rinse buffers 
for the Vectastain® procedure. If the nuclear staining was due to non-specific 
avidin binding, such binding should also have occurred when the negative 
control serum was used, and this did not happen. 
At this time, it is not possible to rule out non-specific staining in the case 
of the stain seen over the nuclei of certain cells. On the other hand, a definite 
reason for such staining is not known. The staining seen in tissues from 
uninfected mice would also lead one to suspect non-specific staining. 
However, it could also indicate that sufficient IFN is locally produced to 
accomplish its normal regulatory functions, and the staining is sensitive 
enough to detect this low level of IFN. 
Comparative staining of both virus-infected and control tissues was 
successfully done at only the 125 hr time period. In that comparison between 
2 mice, all tissues taken from the infected mouse stained darker than those 
from the uninfected mouse. Tissues from virus-infected mice were also 
stained at the 29 hr and the 72 hr time periods. They showed no stronger 
staining than those taken at 125 hr p.i., even though the antiviral activity of 
circulating IFN taken at the 2 earlier time periods was 300- to 1 ,000-fold higher 
than at 125 hr p.i. 
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Staining of tissues from both virus-infected and control mice which 
could be directly compared was attained at only 47 hr p.i., when anti-IFN-a 
was used. The tissues from these 2 mice were stained by use of the 
Histogen® immunostaining kit. Pancreas, lung , spleen, and thymus were the 
only tissues which specifically stained. Most of the stain occurred in areas 
which appeared to be plasma. Smooth muscle cells around large airways of 
the lung tissues (both mice) had dark staining cytoplasm. There was no 
difference in stain intensity between control and virus-infected mouse tissues. 
The negative control serum did not allow staining of any tissue , thus 
indicating that the IFN-y staining patterns were specific, though somewhat 
unanticipated. Tissues from only 2 time periods were successfully stained 
with the anti-IFN-y antiserum. The differences in intensity were not 
overwhelming. Therefore , general conclusions cannot be established without 
further work to determine if such differences are consistent through all time 
periods. 
It is interesting to note that the differences occurred in tissues in which 
high concentrations of T-cells would be expected. It is possible that the virus 
infection could reduce the overall T-cell population or at least reduce one of 
the T-cell sub-species. 
Conclusions. Although the two immunostaining kits examined for 
these studies are advertised for use on formalin-fixed, paraffin-embedded 
ti ssue sections, other fixatives may be best for some of the antigen/tissue 
combinations involved in these studies. In particular, B5 fi xative is better for 
most antigens than is formalin, according to a personal communication from 
Jonathon N. Schumaker, histologist/technical services manager, Lipshaw 
Corp. 
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lmmunostaining for EMC-D virus antigen was only successful in tissues 
other than spleen if the tissues were treated with trypsin. The trypsin 
uncovered some of the virus antigen. It also completely dislodged some of the 
tissue sections from the slides, even though the slides had been treated with 
Elmer's glue to gain better adherence. 
Insulin was well stained in the islets of Langerhans. The islets were 
reduced in size and/or demonstrated a reduced presence of insulin in 
pancreas tissue taken from virus-infected mice beginning at 54 hr p.i. This 
was somewhat surprising since Yoon et al. (15) had shown infiltration of 
leukocytes in the islets of mice inoculated with virus 7 days earlier. No islet 
infiltration of leukocytes was seen in the 5 day period of these experiments. 
Infectious virus yield was shown to increase in pancreas, spleen, 
kidney, liver, lung, and heart beyond the peak of infectious virus seen in the 
plasma. Infectious virus peaked in thymus tissue before it peaked in the 
plasma. 
Circulating IFN titer began a precipitous decline to undetectable levels 
at the time that infected mice began to develop glycosuria. Whether this rapid 
decline in IFN titer had a causative relationship to development of glycosuria 
or not remains to be determined. 
Observations of the relative time of appearance and change in titer of 
various measurable signs of infection, resistance, and diabetes development 
have been made. It is hoped that these preliminary observations will enable a 
more detailed examination of resistance parameters in mouse tissue by 
immunohistochemical methods. The more detailed examination should 
provide some evidence to determine why some mice infected with EMC-D 
virus become diabetic while others recover fully from the virus infection. 
CHAPTER VI 
SPECIAL OBSERVATIONS CONCERNING 
EMC-D VIRUS-INDUCED 
DIABETES IN MICE 
100 
Three significant observations were made during the outlined EMC-D 
virus-induced diabetes research for this dissertation which may appropriately 
be described separately from the remainder of the research . These 
observations are outlined in the following sections. 
Glucose Excretion in the Saliva of EMC·D-Infected Mice. 
Introduction. While attempting to get "obstinate" mice to provide urine samples 
for glucose tests, it was observed that they were more likely to urinate when 
excited than when placid. The observation was also made that mice were 
prone to urinate while biting. In attempts to excite the mice that were not 
excreting urine, Clinistix® test strips were provided as a "chew stick" for mice 
to bite. On the occasions when mice with glycosuria would bite the stick in a 
way that transferred saliva to the indicator pad, a typical glucose reaction 
would occur. This observation was pursued and the results are described as 
follows. 
Materials and methods. Clinistix® or Diastix® test strips and SJUJ mice 
were described in the materials and methods section of Chapter Ill. 
Results and discussion. Both EMC-D virus infected and control mice 
were tested for this reaction . Diastix® test strips were used to obtain 
quantitative glucose readings. Results of the tests are shown in Table VI-I. 
Saliva testing was usually positive for glucose when glycosuria was 
present. Only one test of saliva was negative when glycosuria was 2:2,000 
TABLE VI-I. COMPARISON OF GLUCOSE IN SALIVA AND URINE 
BY CLINISTix® OR DIASTix® TESTS. 
Group No. mice 
Not infected 26 
Infected, no glycosuria 13a 
Infected, with glycosuria 26a 
No. tests 
35 
15 
52 
No. positive 
0 
0 
so·· 
a One mouse tested through day 5 was negative for both saliva and urine 
glucose, but on day 6 and after, was positive for both. This same mouse is 
included in both counts. 
•• P<0.001 
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mg/1 00 mi. The other negative saliva test occurred on a day when the mouse 
provided no urine for testing. The day previous, the urine test on that mouse 
was 500 mg/1 00 ml and 3 days after the negative saliva test, his urine was 
negative for glucose. 
Diastix® readings were usually lower when saliva was tested as 
compared to urine from the same mouse. When the urine reading was ~2.000 
mg/1 00 ml the saliva reading would often match the urine reading. Control 
mice and infected mice without glycosuria were always negative for glucose in 
the saliva. 
The mechanism of glucose secretion in the saliva is not known. It is 
possible that other body secretions also contain glucose when plasma 
glucose levels are high, but this has not been studied. 
Conclusions. Mice with high plasma glucose, sufficient to cause 
glycosuria, also secrete glucose in the saliva. Normal mice did not have 
measurable glucose in their saliva. 
Effect on Diabetogenicity of EMC-D Virus by the Cell Type 
Used for Virus Propagation. Introduction. As noted in Chapter IV, 
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partially purified EMC-0 virus was found to have the same diabetogenic 
properties in mice as crude EMC-D virus pools. An experiment was carried 
out to confirm the observation of Giron et al. (14) that a single passage of 
EMC-0 virus in BHK-21 cells eliminated its diabetogenic properties. In 
contrast to the observation of Giron and his associates, it was found that the 
EMC-D virus passaged one time in BHK-21 cells was equally diabetogenic in 
SJUJ male mice as the EMC-0 virus passaged in L-cells. This experiment is 
described in this section. 
Materials and methods. A crude virus pool, prepared by passage of 
EMC-0 virus a single time in L-cells , was diluted to provide 5 x 10 pfu , 5 x 102 
pfu , or 5 x 103 pfu of virus/mouse when 0.1 ml was injected ip. A crude virus 
pool prepared by passage of the same EMC-0 virus a single time in BHK-21 
cells was diluted to provide 4 x 104 pfu of virus/mouse when 0.1 ml was 
injected ip. Five mice were injected with each concentration of virus and 4 
mice were injected with 0.1 ml of diluent as controls. All mice were male SJUJ 
mice. Titration of both virus pools was done in L-cells as outlined in Chapter 
Ill. Giron et al. (14) also plaque titered their virus pools in L-cells. Their single-
passage virus in BHK-21 cells was used in mice at approximately 1.2 x 104 
pfu/mouse. 
The mice were monitored for glycosuria as explained in Chapter Ill; 
however, the duration of the experiment was extended to 64 days. At 64 days, 
remaining mice were sacrificed and plasma was tested for glucose and 
neutralizing antibody titers as outlined in Chapter Ill. 
Results and discussion. Results of the experiment are shown in Table 
Vl-11. Obviously, the virus passaged once in BHK-21 cells was effective as a 
diabetogenic agent, with 100% of the mice developing diabetes. The earlier 
glycosuria seen in mice given BHK-21 passaged virus was probably due to 
TABLE VI-II. EFFECT OF CELL PASSAGE ON THE DIABETOGENICITY 
OF EMC-D VIRUS IN MALE SJUJ MICE. 
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Virus Cell Qll£QQsuriaa ___ [2all 24 QQS! Vir!JS iOQQIJia!iQD 
cone. passage Pos./total First day Plasma gluQQS!l Neutral. 
(pfu/ all samples Pos.bftotal Titer: antibody 
mouse) were eositive titerd 
5x10 L 5/5 6 1/4 ~338 148 
5x102 L 5/5 8 4/5 ~6 01 229 
5x103 L 5/5 6 1/1 ~800 70 
4x104 BHK-21 5/5 4 4/4 ~785 125 
0 0/4 0/4 128 <10 
a Determined by Clinistix® or Diastix®, after Clinistix® was positive. 
b ~3 S.D. above the mean plasma glucose cone. of control mice. The same 
mice were also glycosuric. 
c Mean of all sampled mice (mg/1 00 ml) . 
d Mean of all sampled mice (units/0.1 ml) . 
the higher dosage of virus given. The day of first appearance of glycosuria 
was dosage dependent in the titration of L-cell passaged virus also. 
Giron's group did use a different strain of mouse (ICR Swiss) than was 
used in these experiments. They also used a different method, a combination 
of plasma glucose levels and glucose tolerance tests, to determine which mice 
were considered diabetic or normal. Neither of these differences would seem 
to account for the dramatic difference of results seen (0% diabetes with Giron's 
group as opposed to 100% diabetes in this study). The reasons for this 
difference are not known. 
Conclusions. Passage of EMC-D virus in L- or BHK-2 1 cells did not 
affect its diabetogenicity. This observation is in contrast to a report by Giron et 
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al. (14). Results of this study indicate that the diabetogenic properties of EMC-
D virus are reasonably stable upon cell passage. 
Correlation of Spontaneous Recovery of Mice from EMC-D 
Virus-Induced Diabetes with Reduced Polydipsia and Polyphagia. 
Introduction. It had previously been noted (Chapter Ill) that most mice with 
EMC-D virus-induced glycosuria developed very wet bedding within a day 
after glycosuria was evident. Some mice had been observed to have normal 
bedding, with no noticeable sticky wetness present, even though they had 
high glycosuria. Mice with normal bedding, whether they had glycosuria or 
not, did not utilize as much water or food as the mice with continuously wet 
bedding. It was decided to measure the water and food intake of the mice at 
different intervals in the experiment to determine if a relationship existed 
between severity of diabetes and food or water consumption . 
Materials and methods. The water bottle of each individually housed 
mouse was weighed each day from days 36 through 40 and again from days 
57 through 60 to determine individual water consumption . Food remaining in 
the feeding trays of cage lids was weighed on each of the above days to 
determine food consumption. Individual mouse weights were recorded on the ' 
same days. The ratio of mean mouse weight per gram of food utilized or per 
gram of water utilized was calculated for each time period. The data for the 
time periods were also combined and the above ratios calculated for the 
combined data. 
Results and discussion. When results of ratios of individual mouse 
weights/weight of food or water consumed were sorted in an ascending order, 
particular groupings of mice were observed. Those with strong glycosuria, 
and wet bedding, at the end of the experiment were grouped as low numbers 
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(high food or water intake). Those mice with normal bedding but which had 
experienced high glycosuria at some time in the experiment were grouped as 
sign ificantly higher numbers. Mean values and standard deviations of the 
ratios for each group are listed in Table Vl-111. There was an obvious differ-
ence in the data obtained from control mice and mice with wet, sticky bedding. 
TABLE VI-lli. RATIO OF MOUSE WEIGHT TO DAILY FOOD OR WATER CONSUMPTION. 
Group MQIJS!l Y:ll t:!Jj Qf fQQQ MQIJS!l Y:ll l'i:JJ. Qf wale[ 
Earl~ Late Combined Earl~ Late Combined 
Diabetic 2.9··±0.5 2.8 .. ±0.6 2.9 .. ±0.5 0.5 .. ±0.1 0.6 .. ±0.2 0.6 .. ±0.1 
Curing or cured 5.8±0.6 6.4±0.7 6.1±0.7 2.6±0.9 3.1±1.0 2.7±0.9 
Controls 6.5±0.2 6.9±0.2 6.7±0.1 2.9±0.2 4.4±0.6 3 .4±0.4 
•• P <0.01, when compared to Curing or cured group. 
Two ranges of data were observed for infected mice. 1) A relatively 
continuous range of values from mice with high glycosuria at the end of the 
experiment. These values ranged from 2.0 to 3.7 for weight/food consumption 
ratio . The ratios for we ight/water consumed ranged from 0.4 to 0.9. 2) A 
range of values for mice that were able to control tendencies toward 
polyphagia and polydipsia. These mice had recovered, or were in the process 
of recovery , from glycosuria. Extremes for this range were 5.2 to 7.2 for food 
consumption and 1.4 to 4.0 for water intake. This range of ratios overlapped 
that of the control, uninfected mice, which had extremes of 6.3 to 7.2 for food 
and 2.7 to 5.3 for water consumption. 
Conclusions. Some of the mice induced to a diabetic state by EMC-D 
virus infection were able to control the polydipsia and polyphagia common to 
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diabetes. These mice recovered spontaneously from the virus-induced 
diabetes. 
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TABLE A-1. TITRATION OF CRUDE vs PURIFIED EMC-0 VIRUS POOLS. 
STANDARD DEVIATIONS FOR PLASMA GLUCOSE AND NEUTRALIZING ANTIBODY. 
Titer of virus Data from mice Plasma glucosea Neutralizing antibodyb 
inoculum sacrificed on !Meao +SQl !llllatl + s !:l l 
(pfu/mouse) (day) Crude Purified Crude Purified 
4 X 103 9 518 .. ±165 541 .. ±180 704±466 556±393 
21 182±20 308.±180 1120±1213 1313±1036 
Combined 406 •• ±211 463 •• ±208 
4 X 104 9 593 •• ±167 517 •• ±120 597±283 443±309 
21 371±288 459 •• ±182 2933±462 1651±701 
Combined 542 •• ±210 499 •• ±136 
4 X 105 9 567 •• ±95 498 •• ±167 354±185 482±209 
21 512 •• ±255 392±357 3203±1730 1731±941 
Combined 551 •• ±148 473 •• ±211 
4 x 105 female 9 358 •• ±125 466 •• ±106 458±248 627±508 
21 170±28 161±25 1613±1381 1878±1284 
Combined 287".±136 269 •• ±162 
9 174±37 0 
21 166±26 0 
Combined 171±33 0 
a mg/100 ml (±S.D.). 
b Units/0.1 ml of plasma. Statistics were not run on this data. 
• P<0.05; •• P<0.01; compared to controls. 
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